疏肝健脾补肾方对CHB患者、HBV转基因小鼠的免疫调节作用研究
|
摘要
1研究设想
乙肝慢性化机制与T淋巴细胞亚群的低反应性、NK活性降低、Th1类细胞因子水平下降等免疫功能不全、体内高滴度病毒含量及对感染细胞的免疫耐受状态有关。目前尚未发现根除HBV的药物，尚未明确HBV免疫耐受发生在哪一个应答环节或关键步骤上。中药复方对慢性乙型肝炎机体免疫功能表现出良好的调节作用，并能有效地促进HBV的清除。从CHB病毒水平与机体免疫状念二者的相关性入手，运用中药复方(疏肝健脾补肾方)对CHB患者、HBV转基因小鼠进行抗病毒和免疫调节作用研究目前尚未见报道。
2研究目的
本课题观察疏肝健脾补肾方联合ADV治疗CHB患者前后病毒DNA水平与免疫功能的相关性，进行抗病毒、免疫调节和中西医结合疗效研究，为防治CHB提供新思路和实验依据。以体外细胞模型来探讨中药抑制HBV复制的机理和意义。并在以往研究基础上观察疏肝健脾补肾方对HBV转基因小鼠的抗病毒和免疫调节作用，探讨中医药治疗HBV的疗效及作用机制。
3研究方法
3．1疏肝健脾补肾方对慢性乙型肝炎患者的免疫学调节机制
51例肝郁脾虚兼脾肾阳虚型CHB患者按随机数字分成A、B、C三组。A为疏肝健脾补肾方组；B为疏肝健脾补肾方+ADV组；C为ADV对照组，每组各17例。A组患者在对症护肝的基础上，服用疏肝健脾补肾方，6个月为1用药疗程；B组患者在对症护肝的基础上，服用疏肝健脾补肾方和ADV；C组患者在对症护肝的基础上，服用ADV。治疗前、治疗后6个月均检测肝功能、免疫功能和病毒学指标。观察CHB患者的临床症状和体征；在自动生化仪上用常规的生化方法检测血清ALT、AST、STB、A／G等指标；采用荧光定量PCR法检测血清HBV DNA，乙肝两对半ELASA法检测HBsAg、HBeAg、抗-HBe；流式细胞仪免疫荧光法检测外周血T淋巴细胞亚群百分率、自然杀伤细胞；放免法检测血清IL-2。
3．2疏肝健脾补肾方体外抗乙肝病毒的实验
用2.2.15细胞作为体外模型，将疏肝健脾补肾方药物原液倍比稀释成7个浓度上药，同时设无药物细胞组进行对照。上药8天后收集上清用ELISA法测定HBsAg、HBeAg。MTT法检测药物细胞毒性，并计算药物对抗原的半数抑制浓度(IC_(50))及治疗指数(TI)。
3．3疏肝健脾补肾方对小鼠的急性毒性实验
实验前把BALB／C小鼠随机分为6组，疏肝健脾补肾方160g／kg／d组、80g／kg／d组、40g／kg／d组、20g／kg／d组、10g／kg／d组和正常对照组(等量生理盐水)，每组10只。以确定不同浓度的疏肝健脾补肾方安全剂量范围。动物禁食16h后一次性灌胃给予受试药物，观察5d，逐日记录中毒症状、死亡情况，死亡动物应及时尸解，记录病变情况，肉眼观察其病变组织。给药后同时观察动物死亡数、耸毛、蜷卧、耳廓苍白或充血、突眼、步履蹒跚、大小便、瘫痪、昏迷、抽搐、步态、呼吸困难等情况。最后断头处死所有动物。
3．4疏肝健脾补肾方对HBV转基因小鼠免疫病理的干预作用
实验动物共分为6组。正常对照组为6-8周龄非HBV转基因雄性BALB／C小鼠10只，灌以等量灭菌等渗生理盐水；SPF级HBV转基因雄性小鼠50只，HbsAg均为阳性，随机分为以下5组：模型组(灌以等量灭菌等渗生理盐水)、疏肝健脾补肾方低剂量组(按10g克生药／kg体重／天灌胃)、疏肝健脾补肾方中剂量组(按20g克生药／kg体重／天灌胃)、疏肝健脾补肾方高剂量组(按40g克生药／kg体重／天灌胃)、ADV组(按50mg／kg体重／天灌胃ADV)，每组10只。每天按时喂药，连续21d。采血前禁食12h，最后1次采血后处死动物。分别于给药前1天(T0)、给药第10天(T10)、给药第21天(T21)、停药后3天(P3)取血，离心取血清，-80℃冻存，用ELASA法检测血清HBsAg，荧光定量PCR法测定血清中HBV DNA。取脾，按常规制备脾单细胞悬液，上流式细胞仪用荧光标记抗体法测定脾T淋巴细胞亚群，用放免法测定脾培养上清中的IL-2、ELISA法测定脾培养上清中的IFNγ。取病变明显处的肝脏作病理学切片及HbcAg免疫组化。
4研究结果
4．1疏肝健脾补肾方对慢性乙型肝炎患者的免疫学调节机制
B组在胁肋胀痛、腹胀便溏、畏寒肢冷、抑郁烦闷、身倦乏力、少腹腰膝冷痛等症状改善方面，优于其它二组。临床疗效方面，三组总有效率之间比较差异均无显著性意义。三组在ALT、AST、TSB、A／G等肝功能恢复方面效果均好，其中B组(疏肝健脾补肾方+ADV)ALT复常率高于单一中药、西药组。三组HBV DNA转阴率总体比较差异有显著性意义，以B组(疏肝健脾补肾方+ADV)转阴率最高。A组、B组、C组治疗前后HBV DNA含量差异有显著性意义，尤以B组为甚。上述结果提示，中西医联合用药比单一中药和单一西药抑制病毒复制的效果更好。三种治法均可增加CD3~+、CD4~+百分比，减少CD8~+细胞百分比，尤以A组、B组增加CD3~+细胞、A组增加CD4~+细胞、B组减少CD8~+细胞的效果更为显著。而ADV单用时增加CD3~+、CD4~+和减少CD8~+的作用则较弱。B组可同时非常显著性提高NK细胞活性和IL-2分泌；C组仅对NK细胞有正向激活作用，对IL-2则无显著影响；相反，A组对NK细胞活性影响不显著，对IL-2水平则有显著提升作用。B组治疗前后CD3~+百分比的增加、NK细胞的增加、CD8~+百分比的减少与HBV DNA载量的减少呈显著正相关。A组治疗前后CD4~+百分比的增加与HBV DNA载量减少呈显著正相关。B组、C组患者各1例偶见药物不良反应。
4．2疏肝健脾补肾方体外抗乙肝病毒的实验
疏肝健脾补肾方对2．2．15细胞的半数毒性浓度TC_(50)为30.28mg／ml，对2．2．15细胞分泌的HBsAg、HBeAg半数抑制浓度为25.96 mg／ml、36.46 mg／ml，治疗指数分别为1.17、0.83。说明疏肝健脾补肾方能低效抑制细胞表达HBsAg，且有毒性作用，而无抑制HBeAg抗原的作用。
4．3疏肝健脾补肾方对小鼠的急性毒性实验
疏肝健脾补肾方160g／kg／d组显示出一定的不良反应。从第2天开始均表现出纳差、饮水量少、乏力、行动迟缓、蜷卧、大便溏泄等情况。在第4天死亡1只，在第5天死亡2只。经解剖发现肝脏呈暗红色，胃肠肿胀并扭曲。可能由于药物的浓度太大，引起小鼠肝脏水肿、出血、坏死所致。而疏肝健脾补肾方80g／kg／d组、40g／kg／d组、20g／kg／d组、10g／kg／d组给药后动物一般状况良好，未发现明显的毒性反应，未见动物死亡。因此，本课题实验所用剂量均在80g／kg／d以下范围进行。
4．4疏肝健脾补肾方对HBV转基因小鼠免疫病理的干预作用
疏肝健脾补肾方中、大剂量及ADV组HBV Tg鼠血清HBsAg转阴率分别在给药后第10天、第21天、停药后第3天进行比较，差异均无显著性意义。ADV具有较好的减少HBV Tg鼠血清HBV DNA载量的作用，但停药后3天有反跳。疏肝健脾补肾方大、中剂量组均具有降低HBV Tg血清HBV DNA载量的作用，尤其以大剂量效果明显，虽然没有减少到ADV组的水平，但治疗前后差异有显著性意义，且停药后无明显反跳，说明中药作用持久、平稳。模型组Tg鼠肝脏病理改变类似临床轻度肝炎表现，随着中药疏肝健脾补肾方浓度的增大，炎症得以缓解，大剂量组的肝板排列整齐，淋巴细胞浸润程度减轻。而ADV治疗小鼠肝组织汇管内见散在的淋巴细胞浸润，无纤维组织增生，但中央静脉周围肝细胞轻度脂肪变性。疏肝健脾补肾方中、大剂量和ADV均能减少肝组织中HbcAg表达，尤其以大剂量明显。疏肝健脾补肾中药能够上调HBV转基因小鼠CD3~+、CD4~+、CD4~+／CD8~+，下调CD8~+T细胞比值水平，具有正向T淋巴细胞免疫调节作用，尤其以大剂量组效果更为显著。ADV也具有提高HBV转基因小鼠细胞免疫的功能(如CD3~+百分比)，但作用相对中药较弱。运用大、中、小剂量疏肝健脾补肾方和ADV均能提高HBV转基因小鼠血清IL-2、IFN-γ含量，与模型组相比差异有显著性意义。且运用大剂量和中剂量的疏肝健脾补肾方治疗后IL-2、IFN-γ水平已高于正常对照组。疏肝健脾补肾方中剂量组CD3~+、IFN-γ与给药前后HBV DNA载量的减少呈显著正相关，疏肝健脾补肾方大剂量组CD4~+、CD8~+、CD4~+／CD8~+与给药前后HBV DNA载量减少呈显著正相关。
5结论
1、疏肝健脾补肾方是较好的免疫调节剂，能明显地增强Th1类细胞因子的分泌，使低下的免疫功能得到改善。
2、疏肝健脾补肾方通过对机体免疫功能的调节，进而抑制HBV复制，这符合中医的“扶正”以“祛邪”理论。
3、ADV具有较好的减少体内血清HBV DNA载量的作用，而疏肝健脾补肾方调节机体免疫功能强于ADV。中西医结合用药能明显改善CHB患者临床症状，具有抗病毒、免疫调节等整体功能。
1 Investigative presumption
The mechanism of chronic hepatitis B is concerned with immunologic inadequacy, forexample, the hyporesponsiveness of T lymphocyte subset, the lower of NK activity and thelower level of Th1 cytokine, virus content of high titer in vivo and the immune tolerance ofinfected cell. Now antiviral drug to eradicate HBV has not been found yet, and the immunetolerance of HBV exactly existing on which reaction link or committed step has not beenidentified. Chinese crude drug complex prescription had favorable regulation on immunefunction of CHB organism, and had effectively facilitated the clearance of HBV. From theassociativity of CHB virus levels and immune state of the organism, now there are fewreports about the studies on Chinese crude drug complex prescription (SHU GAN JIAN PIBU SHENG FANG, SGJPBSF) on the antiviral therapy and immunological regulation forCHB patients and HBV transgenic mice.
2 Aims
We observed the associativity of virus DNA levels and immune function of the organismon CHB patients using SGJPBSF combination with ADV pre-treatment and post-treatmentin this topic, studied antiviral therapy, immunological regulation and the curative effect ofcombination of TCM with Western medicine, offered the new thought and experimentalevidence for prevention and therapy of CHB. We used the vitro cell model to explore themechanism and significance of the traditional Chinese medicine inhibiting the HBVreplication too. On the basis of formerly study and research, we observed theimmunological regulation and antiviral therapy of SGJPBSF on HBV transgenic mice toexplore the curative effect of traditional Chinese medicine for HBV and functionarymechanism.
3 Methods
3.1 the immunologic regulatory mechanism of SHU GAN JIAN PI BU SHENG FANGon CHB patients
51 CHB patients with stagnation of liver-QI with deficiency of the spleen andasdthenic splenonephro-yang were divided into Group A, B, C according to randomnumber. A was SGJPBSF group, B was SGJPBSF plus ADV group, and C was ADV group.Each group had 17 patients. Group A was administrated SGJPBSF on the basis of theaccording to the sign and the protecting from the liver, 6 months each medication. Group Bwas administrated SGJPBSF plus ADV on the basis of the according to the sign and theprotecting from the liver. Group C was administrated ADV on the basis of the according tothe sign and the protecting from the liver. The liver function, immune function and virologyindex of all patients were detected in per-treatment and in post-treatment 6 months. Weobserved the clinic sings and symptoms of patients. The serum levels of ALT, AST, STBand A/G was detected in automatic biochemistry meter by routine biochemistry method.The serum HBV DNA titers were detected by fluorescent quantitation PCR. The serum ofHBsAg, HBeAg and anti-HBe were detected by HBV two half ELASA. The T lymphocytesubset and NK of the peripheral blood were detected by fluorescent-labeled antibody inflow cytometry. IL-2 was detected by radioimmunity.
3.2 the anti-effect experiment of SGJPBSF in vitro
The 2.2.15 cell line was used as cell model. SGJPBSF was diluted into 7 dosage groups.At the same time cell control group was set. After 8 days drug administration, the HBsAgand HBeAg in the supernatant were tested with ELISA assay. The cytotoxicity of drug wasevaluated with the MTT assay, and the IC50 (50%inhibiting concentration) and TI(therapeutic index) of SGJPBSF to antigen were calculated.
3.3 acute toxicity experiment of SGJPBSF to mice
Before the experiment, BALB/C mice had been randomly divided into six groups,SGJPBSF 160g/kg/d, 80g/kg/d, 40g/kg/d, 20g/kg/d, 10g/kg/d and normal control (isodosenormal sodium) to definite the safety dose range of different density SGJPBSF. After allanimals were fasted about 16 hours they were intragastricly administrated one time. Weobserved them for 5 days, recorded daily toxic symptom and death information. The deadmice must be autopsied in time and the pathological changes must be noted. The tissuemust be checked if these pathological changes were observed by naked eye. The number ofdeath, piloerection, tired to lie down, pale auricle or congest, exorbitism, walking haltingly,urination and defecation, plegia, cataphora, convulsion, carriage and anhelation at the sametime were observed. At last, all animals were sacrificed by decapitation.
3.4 the immunopathogenesis intervention of SGJPBSF to HBV transgenic mice
The experimental animals were divided into six groups. The normal control group were6-8 weeks age, 10 non-HBV transgenic male mice, those were intragastric administratedisodose, sterilizing, iso-osmia normal sodium. 50 HBV transgenic male mice of SPF grade,those HbsAg were positive, were randomly divided into 5 groups, model group(wereintragastric administrated isodose, sterilizing, isooosmia normal sodium), low-dose groupof SGJPBSF (were intragastric administrated 10g crude drug /kg body weight /d),middle-dose group of SGJPBSF (were intragastricly administrated 20g crude drug/kgbody weight/d), high-dose group of SGJPBSF (were intragastric administrated 40g crudedrug/kg body weight/d), and ADV group (were intragastric administrated 50g ADV/kgbody weight/d), 10 mice each group. Everyday they were administrated on time, for 21days consecutively. They were fasting for 12 hours before their blood samples were taken.Their blood samples were taken in the time points of T0, T10, T21 and P3 in accordancewith the time point of drug intragastric administration and they were sacrificed after at lastsampling. The serums were collected by centrifugalization, and were keeped under 80℃.The serum HBsAg was detected by ELASA. The serum HBV DNA titers were detected byfluorescent quantitation PCR. The spleens were taken and unicell suspension of the spleenswas prepared by secundum artem. The T lymphocyte subset of the spleen was detected byfluorescent-labeled antibody in flow cytometry. The cytokine was detected in the spleencultivation supematant, for example, IL-2 was detected by radioimmunity, and IFNγwasdetected by ELISA. The liver tissues of obviously pathological changes were taken to dopathology slice and HbcAg immunohistochemistry.
4 Results
4.1 the immunologic regulatory mechanism of SHU GAN JIAN PI BU SHENG FANGon CHB patients
The symptoms of hypochondrium distending pain, abdominal distention, loose stool,feeling chill, cold limbs, depression, discomfort, tired body, debilitation, psychroalgia inthe lower abdomen, lumbar and knee in Group B were superior to other groups. Inclinically therapeutic effect, there was no significant difference in total effective rate ofthree groups. The liver functional recoveries of alanine aminotransferase, aspartateaminotransferase, total bilirubin, A/G were good in three groups, but the ALTnormalization rate in Group B (SGJPBSF plus ADV) was higher than that of in Group A(SGJPBSF) and Group C (ADV). There was significant difference in three groups about therate of negative transfer of HBV DNA, and the rate in Group B was highest. There weresignificant differences of the serum titers of HBV DNA in three groups between the pre-treatment and post-treatment, especially in Group B. Those results suggest that theeffect of inhibiting viral replication in combination medication of TCM with Westernmedicine was superior to single Chinese crude drug and single western medicine. Threetherapeutic methods all could increase the ratio of CD3~+, CD4~+ cell and decrease the ratioof CD8~+ cell, especially increasing the ratio of CD3~+ in Group A and Group B, increasingthe ratio of CD4~+ in Group A, decreasing the ratio of CD8~+ in Group B were verysignificant. When using ADV treatment, the effect of increasing the CD3~+, CD4~+ cell ratioand decreasing the CD8~+ cell ratio in single was mild. The raising of NK cytoactive andIL-2 secretion in Group B was very significantly. Group C had the norientation activationon NK, but had no significant effect on IL-2. Opposite, Group A had no significantnorientation activation on NK, but had significant upgrading effect on IL-2. The increasingof CD4~+ and NK and the decreasing of CD8~+ T cell ratio were significantly positivecorrelation to the decreasing of HBV DNA titers between the pre-treatment andpost-treatment in Group B. The increasing of CD4~+ cell ratio was significantly positivecorrelation to the decreasing of HBV DNA titers between the prior treatment andpost-treatment in Group A. There was one example drug adverse reaction in Group B andGroup C respectively.
4.2 the anti-effect experiment of SGJPBSF in vitro
The TC50 of SGJPBSF to 2.2.15 cell line was 30.28mg/ml. The IC50 of SGJPBSF toHBsAg, HBeAg was 25.96mg/ml and 36.46mg/ml respectively, and the TI of SGJPBSFwas 1.17 and 0.83 respectively. It suggested SGJPBSF could inhibit the HBsAg express of2.2.15 cell line, but it could have toxic effect and could not inhibit the HBeAg express.
4.3 acute toxicity experiment of SGJPBSF to mice
The mice of SGJPBSF 160g/kg/d showed some adverse effect. From the second day, themice showed seldom eating, seldom drinking water, debilitation, moving slowly, tiring tolie down, loose stool, and so on. One mouse died in 4th day and two mice died in the 5thday. Under the anatomy, the livers of three died mice were madder red and their stomachintestines were swelling and twist, possibly because too high pharmacal density could causedropsy, hemorrhage and necrosis of murine liver. The general condition was good afteradministration in the mice of SGJPBSF 80g/kg/d, 40g/kg/d, 20g/kg/d, 10g/kg/d, obviouslytoxic reaction was not found, and there was not dead animal. So all dose used in followexperiment was below 80g/kg/d.
4.4 the immunopathogenesis intervention of SGJPBSF to HBV transgenic mice
The HBsAg sero-nagative rate of HBV Tg in high-dose group of SGJPBSF,middle-dose group and ADV group had no significant difference on T10, T21 after administration and P3. ADV could reduce the serum HBV DNA titers of HBV Tg, butthere was markedly rebound on 3rd after drug withdrawal. High-dose SGJPBSF andmiddle-dose both decreased the serum HBV DNA titers of HBV Tg, especially high-doseSGJPBSF, although the serum HBV DNA titers were not decreased to the level of ADVgroup, there was significant difference between the pre-treatment and post-treatment, andthere was no rebound after drug withdrawal, its effect was steady for a long time. The liverpathology change of model HBV Tg was similar to the appearance of the clinical lightlyhepatitis, and along with the increasing SGJPBSF density, the liver inflammation wasrelieved. The hepatic plate of high-dose SGJPBSF lined up in order and the degree oflymphocyte soakage was relieved. But there was still sporadic lymphocyte soakage in theconverge duct of hepatic tissue of ADV group, there was no fibroplasias, but in the centralveins surrounding there was some lightly hepatocyte adipose degeneration. Themiddle-dose, high-dose SGJPBSF and ADV all could decrease the HbcAg express in thehepatic tissue, especially high-dose SGJPBSF. SGJPBSF could up-regulate the ratio ofCD3~+, CD4~+ and CD4~+/CD8~+ cells of HBV Tg, and could down-regulate the ratio of CD8~+T cell. So it had the norientation effect of T lymphocyte immunological regulationespecially high-dose SGJPBSF. ADV had the effect of increasing cytoimmunity of HBVTg too (for example, CD3~+ cell percentage), but its function was weaker than the traditionalChinese medicine. The low-dose, middle-dose, high-dose SGJPBSF and ADV all couldincrease the serum level of IL-2 and IFN-γof HBV Tg, and there was significant differenceas compared to the model group. And the level of IL-2 and IFN-γin middle-dose, high-doseSGJPBSF had far surpassed the normal control after treatment. The ratio of CD3~+ T cell andthe level of IFN-γwere significantly positive correlation to the decreasing of HBV DNAtiters between the pre-treatment and post-treatment in middle-dose. The ratio of CD4~+,CD8~+ and CD4~+/CD8~+ T cells were significantly positive correlation to the decrease ofHBV DNA titers between the pre-treatment and post-treatment in high-dose.
5 Conclusions
5.1 SGJPBSF was fine immunomodulator, and it could significantly strengthen thesecretion of Th1 cytokine and could improve the lower immune function.
5.2 It suggested that SGJPBSF could clear up and inhibit HBV through regulating theimmune function of organism. It was consistent with TCM theory of strengthening bodyresistance to eliminating pathogen.
5.3 ADV could have the better effect of decreasing the serum HBV DNA titers thanSGJPBSF, but SGJPBSF could have the better effect of regulating immune function than ADV. United medication of SGJPBSF plus ADV is shown to have the better clinicaleffect of improving symptoms, inhibiting the HBV duplication and regulating theabnormal immune function in CHB patients.
乙肝慢性化机制与T淋巴细胞亚群的低反应性、NK活性降低、Th1类细胞因子水平下降等免疫功能不全、体内高滴度病毒含量及对感染细胞的免疫耐受状态有关。目前尚未发现根除HBV的药物，尚未明确HBV免疫耐受发生在哪一个应答环节或关键步骤上。中药复方对慢性乙型肝炎机体免疫功能表现出良好的调节作用，并能有效地促进HBV的清除。从CHB病毒水平与机体免疫状念二者的相关性入手，运用中药复方(疏肝健脾补肾方)对CHB患者、HBV转基因小鼠进行抗病毒和免疫调节作用研究目前尚未见报道。
2研究目的
本课题观察疏肝健脾补肾方联合ADV治疗CHB患者前后病毒DNA水平与免疫功能的相关性，进行抗病毒、免疫调节和中西医结合疗效研究，为防治CHB提供新思路和实验依据。以体外细胞模型来探讨中药抑制HBV复制的机理和意义。并在以往研究基础上观察疏肝健脾补肾方对HBV转基因小鼠的抗病毒和免疫调节作用，探讨中医药治疗HBV的疗效及作用机制。
3研究方法
3．1疏肝健脾补肾方对慢性乙型肝炎患者的免疫学调节机制
51例肝郁脾虚兼脾肾阳虚型CHB患者按随机数字分成A、B、C三组。A为疏肝健脾补肾方组；B为疏肝健脾补肾方+ADV组；C为ADV对照组，每组各17例。A组患者在对症护肝的基础上，服用疏肝健脾补肾方，6个月为1用药疗程；B组患者在对症护肝的基础上，服用疏肝健脾补肾方和ADV；C组患者在对症护肝的基础上，服用ADV。治疗前、治疗后6个月均检测肝功能、免疫功能和病毒学指标。观察CHB患者的临床症状和体征；在自动生化仪上用常规的生化方法检测血清ALT、AST、STB、A／G等指标；采用荧光定量PCR法检测血清HBV DNA，乙肝两对半ELASA法检测HBsAg、HBeAg、抗-HBe；流式细胞仪免疫荧光法检测外周血T淋巴细胞亚群百分率、自然杀伤细胞；放免法检测血清IL-2。
3．2疏肝健脾补肾方体外抗乙肝病毒的实验
用2.2.15细胞作为体外模型，将疏肝健脾补肾方药物原液倍比稀释成7个浓度上药，同时设无药物细胞组进行对照。上药8天后收集上清用ELISA法测定HBsAg、HBeAg。MTT法检测药物细胞毒性，并计算药物对抗原的半数抑制浓度(IC_(50))及治疗指数(TI)。
3．3疏肝健脾补肾方对小鼠的急性毒性实验
实验前把BALB／C小鼠随机分为6组，疏肝健脾补肾方160g／kg／d组、80g／kg／d组、40g／kg／d组、20g／kg／d组、10g／kg／d组和正常对照组(等量生理盐水)，每组10只。以确定不同浓度的疏肝健脾补肾方安全剂量范围。动物禁食16h后一次性灌胃给予受试药物，观察5d，逐日记录中毒症状、死亡情况，死亡动物应及时尸解，记录病变情况，肉眼观察其病变组织。给药后同时观察动物死亡数、耸毛、蜷卧、耳廓苍白或充血、突眼、步履蹒跚、大小便、瘫痪、昏迷、抽搐、步态、呼吸困难等情况。最后断头处死所有动物。
3．4疏肝健脾补肾方对HBV转基因小鼠免疫病理的干预作用
实验动物共分为6组。正常对照组为6-8周龄非HBV转基因雄性BALB／C小鼠10只，灌以等量灭菌等渗生理盐水；SPF级HBV转基因雄性小鼠50只，HbsAg均为阳性，随机分为以下5组：模型组(灌以等量灭菌等渗生理盐水)、疏肝健脾补肾方低剂量组(按10g克生药／kg体重／天灌胃)、疏肝健脾补肾方中剂量组(按20g克生药／kg体重／天灌胃)、疏肝健脾补肾方高剂量组(按40g克生药／kg体重／天灌胃)、ADV组(按50mg／kg体重／天灌胃ADV)，每组10只。每天按时喂药，连续21d。采血前禁食12h，最后1次采血后处死动物。分别于给药前1天(T0)、给药第10天(T10)、给药第21天(T21)、停药后3天(P3)取血，离心取血清，-80℃冻存，用ELASA法检测血清HBsAg，荧光定量PCR法测定血清中HBV DNA。取脾，按常规制备脾单细胞悬液，上流式细胞仪用荧光标记抗体法测定脾T淋巴细胞亚群，用放免法测定脾培养上清中的IL-2、ELISA法测定脾培养上清中的IFNγ。取病变明显处的肝脏作病理学切片及HbcAg免疫组化。
4研究结果
4．1疏肝健脾补肾方对慢性乙型肝炎患者的免疫学调节机制
B组在胁肋胀痛、腹胀便溏、畏寒肢冷、抑郁烦闷、身倦乏力、少腹腰膝冷痛等症状改善方面，优于其它二组。临床疗效方面，三组总有效率之间比较差异均无显著性意义。三组在ALT、AST、TSB、A／G等肝功能恢复方面效果均好，其中B组(疏肝健脾补肾方+ADV)ALT复常率高于单一中药、西药组。三组HBV DNA转阴率总体比较差异有显著性意义，以B组(疏肝健脾补肾方+ADV)转阴率最高。A组、B组、C组治疗前后HBV DNA含量差异有显著性意义，尤以B组为甚。上述结果提示，中西医联合用药比单一中药和单一西药抑制病毒复制的效果更好。三种治法均可增加CD3~+、CD4~+百分比，减少CD8~+细胞百分比，尤以A组、B组增加CD3~+细胞、A组增加CD4~+细胞、B组减少CD8~+细胞的效果更为显著。而ADV单用时增加CD3~+、CD4~+和减少CD8~+的作用则较弱。B组可同时非常显著性提高NK细胞活性和IL-2分泌；C组仅对NK细胞有正向激活作用，对IL-2则无显著影响；相反，A组对NK细胞活性影响不显著，对IL-2水平则有显著提升作用。B组治疗前后CD3~+百分比的增加、NK细胞的增加、CD8~+百分比的减少与HBV DNA载量的减少呈显著正相关。A组治疗前后CD4~+百分比的增加与HBV DNA载量减少呈显著正相关。B组、C组患者各1例偶见药物不良反应。
4．2疏肝健脾补肾方体外抗乙肝病毒的实验
疏肝健脾补肾方对2．2．15细胞的半数毒性浓度TC_(50)为30.28mg／ml，对2．2．15细胞分泌的HBsAg、HBeAg半数抑制浓度为25.96 mg／ml、36.46 mg／ml，治疗指数分别为1.17、0.83。说明疏肝健脾补肾方能低效抑制细胞表达HBsAg，且有毒性作用，而无抑制HBeAg抗原的作用。
4．3疏肝健脾补肾方对小鼠的急性毒性实验
疏肝健脾补肾方160g／kg／d组显示出一定的不良反应。从第2天开始均表现出纳差、饮水量少、乏力、行动迟缓、蜷卧、大便溏泄等情况。在第4天死亡1只，在第5天死亡2只。经解剖发现肝脏呈暗红色，胃肠肿胀并扭曲。可能由于药物的浓度太大，引起小鼠肝脏水肿、出血、坏死所致。而疏肝健脾补肾方80g／kg／d组、40g／kg／d组、20g／kg／d组、10g／kg／d组给药后动物一般状况良好，未发现明显的毒性反应，未见动物死亡。因此，本课题实验所用剂量均在80g／kg／d以下范围进行。
4．4疏肝健脾补肾方对HBV转基因小鼠免疫病理的干预作用
疏肝健脾补肾方中、大剂量及ADV组HBV Tg鼠血清HBsAg转阴率分别在给药后第10天、第21天、停药后第3天进行比较，差异均无显著性意义。ADV具有较好的减少HBV Tg鼠血清HBV DNA载量的作用，但停药后3天有反跳。疏肝健脾补肾方大、中剂量组均具有降低HBV Tg血清HBV DNA载量的作用，尤其以大剂量效果明显，虽然没有减少到ADV组的水平，但治疗前后差异有显著性意义，且停药后无明显反跳，说明中药作用持久、平稳。模型组Tg鼠肝脏病理改变类似临床轻度肝炎表现，随着中药疏肝健脾补肾方浓度的增大，炎症得以缓解，大剂量组的肝板排列整齐，淋巴细胞浸润程度减轻。而ADV治疗小鼠肝组织汇管内见散在的淋巴细胞浸润，无纤维组织增生，但中央静脉周围肝细胞轻度脂肪变性。疏肝健脾补肾方中、大剂量和ADV均能减少肝组织中HbcAg表达，尤其以大剂量明显。疏肝健脾补肾中药能够上调HBV转基因小鼠CD3~+、CD4~+、CD4~+／CD8~+，下调CD8~+T细胞比值水平，具有正向T淋巴细胞免疫调节作用，尤其以大剂量组效果更为显著。ADV也具有提高HBV转基因小鼠细胞免疫的功能(如CD3~+百分比)，但作用相对中药较弱。运用大、中、小剂量疏肝健脾补肾方和ADV均能提高HBV转基因小鼠血清IL-2、IFN-γ含量，与模型组相比差异有显著性意义。且运用大剂量和中剂量的疏肝健脾补肾方治疗后IL-2、IFN-γ水平已高于正常对照组。疏肝健脾补肾方中剂量组CD3~+、IFN-γ与给药前后HBV DNA载量的减少呈显著正相关，疏肝健脾补肾方大剂量组CD4~+、CD8~+、CD4~+／CD8~+与给药前后HBV DNA载量减少呈显著正相关。
5结论
1、疏肝健脾补肾方是较好的免疫调节剂，能明显地增强Th1类细胞因子的分泌，使低下的免疫功能得到改善。
2、疏肝健脾补肾方通过对机体免疫功能的调节，进而抑制HBV复制，这符合中医的“扶正”以“祛邪”理论。
3、ADV具有较好的减少体内血清HBV DNA载量的作用，而疏肝健脾补肾方调节机体免疫功能强于ADV。中西医结合用药能明显改善CHB患者临床症状，具有抗病毒、免疫调节等整体功能。
1 Investigative presumption
The mechanism of chronic hepatitis B is concerned with immunologic inadequacy, forexample, the hyporesponsiveness of T lymphocyte subset, the lower of NK activity and thelower level of Th1 cytokine, virus content of high titer in vivo and the immune tolerance ofinfected cell. Now antiviral drug to eradicate HBV has not been found yet, and the immunetolerance of HBV exactly existing on which reaction link or committed step has not beenidentified. Chinese crude drug complex prescription had favorable regulation on immunefunction of CHB organism, and had effectively facilitated the clearance of HBV. From theassociativity of CHB virus levels and immune state of the organism, now there are fewreports about the studies on Chinese crude drug complex prescription (SHU GAN JIAN PIBU SHENG FANG, SGJPBSF) on the antiviral therapy and immunological regulation forCHB patients and HBV transgenic mice.
2 Aims
We observed the associativity of virus DNA levels and immune function of the organismon CHB patients using SGJPBSF combination with ADV pre-treatment and post-treatmentin this topic, studied antiviral therapy, immunological regulation and the curative effect ofcombination of TCM with Western medicine, offered the new thought and experimentalevidence for prevention and therapy of CHB. We used the vitro cell model to explore themechanism and significance of the traditional Chinese medicine inhibiting the HBVreplication too. On the basis of formerly study and research, we observed theimmunological regulation and antiviral therapy of SGJPBSF on HBV transgenic mice toexplore the curative effect of traditional Chinese medicine for HBV and functionarymechanism.
3 Methods
3.1 the immunologic regulatory mechanism of SHU GAN JIAN PI BU SHENG FANGon CHB patients
51 CHB patients with stagnation of liver-QI with deficiency of the spleen andasdthenic splenonephro-yang were divided into Group A, B, C according to randomnumber. A was SGJPBSF group, B was SGJPBSF plus ADV group, and C was ADV group.Each group had 17 patients. Group A was administrated SGJPBSF on the basis of theaccording to the sign and the protecting from the liver, 6 months each medication. Group Bwas administrated SGJPBSF plus ADV on the basis of the according to the sign and theprotecting from the liver. Group C was administrated ADV on the basis of the according tothe sign and the protecting from the liver. The liver function, immune function and virologyindex of all patients were detected in per-treatment and in post-treatment 6 months. Weobserved the clinic sings and symptoms of patients. The serum levels of ALT, AST, STBand A/G was detected in automatic biochemistry meter by routine biochemistry method.The serum HBV DNA titers were detected by fluorescent quantitation PCR. The serum ofHBsAg, HBeAg and anti-HBe were detected by HBV two half ELASA. The T lymphocytesubset and NK of the peripheral blood were detected by fluorescent-labeled antibody inflow cytometry. IL-2 was detected by radioimmunity.
3.2 the anti-effect experiment of SGJPBSF in vitro
The 2.2.15 cell line was used as cell model. SGJPBSF was diluted into 7 dosage groups.At the same time cell control group was set. After 8 days drug administration, the HBsAgand HBeAg in the supernatant were tested with ELISA assay. The cytotoxicity of drug wasevaluated with the MTT assay, and the IC50 (50%inhibiting concentration) and TI(therapeutic index) of SGJPBSF to antigen were calculated.
3.3 acute toxicity experiment of SGJPBSF to mice
Before the experiment, BALB/C mice had been randomly divided into six groups,SGJPBSF 160g/kg/d, 80g/kg/d, 40g/kg/d, 20g/kg/d, 10g/kg/d and normal control (isodosenormal sodium) to definite the safety dose range of different density SGJPBSF. After allanimals were fasted about 16 hours they were intragastricly administrated one time. Weobserved them for 5 days, recorded daily toxic symptom and death information. The deadmice must be autopsied in time and the pathological changes must be noted. The tissuemust be checked if these pathological changes were observed by naked eye. The number ofdeath, piloerection, tired to lie down, pale auricle or congest, exorbitism, walking haltingly,urination and defecation, plegia, cataphora, convulsion, carriage and anhelation at the sametime were observed. At last, all animals were sacrificed by decapitation.
3.4 the immunopathogenesis intervention of SGJPBSF to HBV transgenic mice
The experimental animals were divided into six groups. The normal control group were6-8 weeks age, 10 non-HBV transgenic male mice, those were intragastric administratedisodose, sterilizing, iso-osmia normal sodium. 50 HBV transgenic male mice of SPF grade,those HbsAg were positive, were randomly divided into 5 groups, model group(wereintragastric administrated isodose, sterilizing, isooosmia normal sodium), low-dose groupof SGJPBSF (were intragastric administrated 10g crude drug /kg body weight /d),middle-dose group of SGJPBSF (were intragastricly administrated 20g crude drug/kgbody weight/d), high-dose group of SGJPBSF (were intragastric administrated 40g crudedrug/kg body weight/d), and ADV group (were intragastric administrated 50g ADV/kgbody weight/d), 10 mice each group. Everyday they were administrated on time, for 21days consecutively. They were fasting for 12 hours before their blood samples were taken.Their blood samples were taken in the time points of T0, T10, T21 and P3 in accordancewith the time point of drug intragastric administration and they were sacrificed after at lastsampling. The serums were collected by centrifugalization, and were keeped under 80℃.The serum HBsAg was detected by ELASA. The serum HBV DNA titers were detected byfluorescent quantitation PCR. The spleens were taken and unicell suspension of the spleenswas prepared by secundum artem. The T lymphocyte subset of the spleen was detected byfluorescent-labeled antibody in flow cytometry. The cytokine was detected in the spleencultivation supematant, for example, IL-2 was detected by radioimmunity, and IFNγwasdetected by ELISA. The liver tissues of obviously pathological changes were taken to dopathology slice and HbcAg immunohistochemistry.
4 Results
4.1 the immunologic regulatory mechanism of SHU GAN JIAN PI BU SHENG FANGon CHB patients
The symptoms of hypochondrium distending pain, abdominal distention, loose stool,feeling chill, cold limbs, depression, discomfort, tired body, debilitation, psychroalgia inthe lower abdomen, lumbar and knee in Group B were superior to other groups. Inclinically therapeutic effect, there was no significant difference in total effective rate ofthree groups. The liver functional recoveries of alanine aminotransferase, aspartateaminotransferase, total bilirubin, A/G were good in three groups, but the ALTnormalization rate in Group B (SGJPBSF plus ADV) was higher than that of in Group A(SGJPBSF) and Group C (ADV). There was significant difference in three groups about therate of negative transfer of HBV DNA, and the rate in Group B was highest. There weresignificant differences of the serum titers of HBV DNA in three groups between the pre-treatment and post-treatment, especially in Group B. Those results suggest that theeffect of inhibiting viral replication in combination medication of TCM with Westernmedicine was superior to single Chinese crude drug and single western medicine. Threetherapeutic methods all could increase the ratio of CD3~+, CD4~+ cell and decrease the ratioof CD8~+ cell, especially increasing the ratio of CD3~+ in Group A and Group B, increasingthe ratio of CD4~+ in Group A, decreasing the ratio of CD8~+ in Group B were verysignificant. When using ADV treatment, the effect of increasing the CD3~+, CD4~+ cell ratioand decreasing the CD8~+ cell ratio in single was mild. The raising of NK cytoactive andIL-2 secretion in Group B was very significantly. Group C had the norientation activationon NK, but had no significant effect on IL-2. Opposite, Group A had no significantnorientation activation on NK, but had significant upgrading effect on IL-2. The increasingof CD4~+ and NK and the decreasing of CD8~+ T cell ratio were significantly positivecorrelation to the decreasing of HBV DNA titers between the pre-treatment andpost-treatment in Group B. The increasing of CD4~+ cell ratio was significantly positivecorrelation to the decreasing of HBV DNA titers between the prior treatment andpost-treatment in Group A. There was one example drug adverse reaction in Group B andGroup C respectively.
4.2 the anti-effect experiment of SGJPBSF in vitro
The TC50 of SGJPBSF to 2.2.15 cell line was 30.28mg/ml. The IC50 of SGJPBSF toHBsAg, HBeAg was 25.96mg/ml and 36.46mg/ml respectively, and the TI of SGJPBSFwas 1.17 and 0.83 respectively. It suggested SGJPBSF could inhibit the HBsAg express of2.2.15 cell line, but it could have toxic effect and could not inhibit the HBeAg express.
4.3 acute toxicity experiment of SGJPBSF to mice
The mice of SGJPBSF 160g/kg/d showed some adverse effect. From the second day, themice showed seldom eating, seldom drinking water, debilitation, moving slowly, tiring tolie down, loose stool, and so on. One mouse died in 4th day and two mice died in the 5thday. Under the anatomy, the livers of three died mice were madder red and their stomachintestines were swelling and twist, possibly because too high pharmacal density could causedropsy, hemorrhage and necrosis of murine liver. The general condition was good afteradministration in the mice of SGJPBSF 80g/kg/d, 40g/kg/d, 20g/kg/d, 10g/kg/d, obviouslytoxic reaction was not found, and there was not dead animal. So all dose used in followexperiment was below 80g/kg/d.
4.4 the immunopathogenesis intervention of SGJPBSF to HBV transgenic mice
The HBsAg sero-nagative rate of HBV Tg in high-dose group of SGJPBSF,middle-dose group and ADV group had no significant difference on T10, T21 after administration and P3. ADV could reduce the serum HBV DNA titers of HBV Tg, butthere was markedly rebound on 3rd after drug withdrawal. High-dose SGJPBSF andmiddle-dose both decreased the serum HBV DNA titers of HBV Tg, especially high-doseSGJPBSF, although the serum HBV DNA titers were not decreased to the level of ADVgroup, there was significant difference between the pre-treatment and post-treatment, andthere was no rebound after drug withdrawal, its effect was steady for a long time. The liverpathology change of model HBV Tg was similar to the appearance of the clinical lightlyhepatitis, and along with the increasing SGJPBSF density, the liver inflammation wasrelieved. The hepatic plate of high-dose SGJPBSF lined up in order and the degree oflymphocyte soakage was relieved. But there was still sporadic lymphocyte soakage in theconverge duct of hepatic tissue of ADV group, there was no fibroplasias, but in the centralveins surrounding there was some lightly hepatocyte adipose degeneration. Themiddle-dose, high-dose SGJPBSF and ADV all could decrease the HbcAg express in thehepatic tissue, especially high-dose SGJPBSF. SGJPBSF could up-regulate the ratio ofCD3~+, CD4~+ and CD4~+/CD8~+ cells of HBV Tg, and could down-regulate the ratio of CD8~+T cell. So it had the norientation effect of T lymphocyte immunological regulationespecially high-dose SGJPBSF. ADV had the effect of increasing cytoimmunity of HBVTg too (for example, CD3~+ cell percentage), but its function was weaker than the traditionalChinese medicine. The low-dose, middle-dose, high-dose SGJPBSF and ADV all couldincrease the serum level of IL-2 and IFN-γof HBV Tg, and there was significant differenceas compared to the model group. And the level of IL-2 and IFN-γin middle-dose, high-doseSGJPBSF had far surpassed the normal control after treatment. The ratio of CD3~+ T cell andthe level of IFN-γwere significantly positive correlation to the decreasing of HBV DNAtiters between the pre-treatment and post-treatment in middle-dose. The ratio of CD4~+,CD8~+ and CD4~+/CD8~+ T cells were significantly positive correlation to the decrease ofHBV DNA titers between the pre-treatment and post-treatment in high-dose.
5 Conclusions
5.1 SGJPBSF was fine immunomodulator, and it could significantly strengthen thesecretion of Th1 cytokine and could improve the lower immune function.
5.2 It suggested that SGJPBSF could clear up and inhibit HBV through regulating theimmune function of organism. It was consistent with TCM theory of strengthening bodyresistance to eliminating pathogen.
5.3 ADV could have the better effect of decreasing the serum HBV DNA titers thanSGJPBSF, but SGJPBSF could have the better effect of regulating immune function than ADV. United medication of SGJPBSF plus ADV is shown to have the better clinicaleffect of improving symptoms, inhibiting the HBV duplication and regulating theabnormal immune function in CHB patients.
引文
1 Wang FS. Current status and prospects of studies on human genetic allelses associated with hepatitis B virus infection. World J Gastroenterol. 2003 9:641-644
2 Luo KX, Zhu YF (eds). Hepatitis B: basic biology and clinical science. People's Medical Publishing House, 2001, Beijing
3 姚云清，张定凤．乙型肝炎病毒感染、复制及其清除机制．中华肝脏病杂志，2002，10(5)：398-400
4 李山．HBV感染后的Th1／Th2细胞应答．医学文选，2000，19(5)：752-754
5 刘林华．阿德福韦酯抗乙肝病毒治疗进展．国外医学·病毒学分册，2005，12(5)：154
6 Vingerhoets J, Michielsen P, Vanham G, et al. HBV-specific lymphoproliferative and cytokine responses with chronic hepatitis. J Hepatol, 1998,28:8-16
7 刘光伟．慢性乙型肝炎免疫病理及中医药免疫调节治疗研究概况．上海中医药大学学报，2005，19(1)：59-61
8 Chisari, F.V., Ferrafi, C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995,13:29-60
9 王福生．天然免疫应答清除HBV的作用及其临床免疫治疗的前景．中华医学杂志，2005，85(17)：1158-1159
10 U. Protzer, H. Schaller. Immune Escape by Hepatitis B Viruses. Virus Genes 2000,21:1/2, 27-37,
11 Janeway C.A, Travers P., Immunobiology. The Immune System in Health and Disease. Current Biology Ltd., London, 1998, 9:1-9:46
12 温帆渊．慢性乙型肝炎抗病毒治疗的现状及展望．现代医药卫生，2005，21(10)：1183-1184
13 Rehermann B, NascimbeniM. Immunology of hepatitis B virus and hepatitis C virus infection Nat Rev Immunol, 2005, 5:215-229
14 Guidotti L.G., Rochford R, Chung I, et al. Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection. Science 1999,284: 825-829
15 Yang P M, Pu I J, Lai M Y, et al. Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic type B hepatitis, with special emphasis on the activation status of lymphocytes. AMJ Gastroenterol, 1998, 83: 948-951
16 骆抗生．乙型肝炎基础与临床．北京：人民出版社．第2版，2001：188-189
17 Maini MK, Boni C, Lee CK, et al. The role of virus specific CD8 + cells in liver damage and viral control during persistent hepatitis B virus infection. J Ex p Med, 2000,191(8): 1269-1280
18 Chisafi FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. A m J Pathol, 2000, 156 (4): 1117-1132
19 Ando K, Moriyadma T, Guidotti L G, et al. Mechanisms of class Ⅰ restricted immunopathology. A transgenic mouse model of fulnuinant hepatitis. J Ex p Med, 1993, 178 (5): 1541-1554
20 Gobbold S, Waldmmm H. Infectious Tolerance. Curr Opin Immunol,1999, 10:518-524
21 Kung T. Impaired clonal expansion in athymic nude CD4~+ / CD8~+ T cells. J Immunol, 2001, 140:3727-3729
22 Del-Prete G, Maggi E, Romagnani, S. Human Th1 and Th2 cells: functional properties, mechanisms of regulation, and role in disease. Lad Invest, 1994,70:299-306
23 骆抗先．乙型肝炎的基础和临床．北京：人民卫生出版社．第1版．1997：115-131
24 Mc Farlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother, 1999, 53: 255-263
25 Jens S, Jennifer P, Alexandra K, et al. Silibinin protects mice from T cell-dependent liver injury. J Hepatology, 2003, 39:333-400
26 Mlilich DR. Influence of T-helper cell subsets and cross regulation in hepatitis B virus infection. J Viral Hepat, 1997, 4(suppl 2):48-59
27 Fukuda R, Ishimura N, Nguyen TX, et al. The expression of and IL-2, IL-4 and interferon-gamma(IFN-gamma) mRNA/using liver biopsies at different prases of acute exaceberbation if chronic hepatitis B. Clin Exp Immunol, 1995,100(3):446-451
28 Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001, 19:65-91
29 Nayersina, R., Fowler, P., Guilhot, S, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J. Immunol. 1993, 150:4659—4671
30 Kakimi K, Lane TE, Chisari FV, Guidotti LG. Cutting edge: inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol. 2001, 167:6701-6705
31 Bream JH, Carrington M, O'Toole S, et al. Polymorphisms of the human IFNG gene noneoding regions. Immunogenetics. 2000, 51:50-58
32 Sato S, Kawashing H, Oshiro H, et al. A Virological and immunological outcome with Epstein-Barr virus-associated hemophagocytec syndrome. J Clin Virol.2004, 31:235-238
33 Shao C, Qu J, He l, et al. Transient overexprission of a interferon promotes Aapergillus clerarance in invasive pulmonary aspergillosis. Clin Exp Immunol. 2005, 142:233-241
34 Mizuhara, H, Uno, M, Seki, N, et al. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology, 1996, 23:1608-1615
35 Billiau A, Heremans H, Vermeire K, Matthys P. Immunomodulatory properties of interferon-gamma. An update. Ann N Y Acad Sci. 1998,856:22-23
36 Billiau, A. Interferon-gamma: Biology and role in pathogenesis. Adv. Immunol. 1996, 162:61-130
37 Schultz U, Chisari FV. Recombinant duck interferon gamma inhibits duck hepatitis B virus replication in primary hepatocytes. J Virol, 1999,73:3162-3168
38 Guidotti LG, Matzke B, Chisari FV. Hepatitis B vires replication is cell cycle independent during liver regeneratio in transgenic mice. J Virol, 1997,71:4804-4808
39 Uprichard SL, Wieland SF, Althage A, Chisari FV. Transcriptional and posttranscriptional control of hepatitis Bvirus gene expression. Proc Natl Acad Sci USA. 2003, 100:1310-1315
40 Guidotti LG, McClary H, Loudis JM, et al. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med, 2000,191 : 1247-1252
41 张飚，隋涛，于秀英，等．慢性乙肝患者外周血单个核细胞凋亡及细胞因子检测的意义．临床肝胆病杂志，2004，20(4)：138-140
42 陈焰，田德英．治疗对慢性乙型肝炎抗病毒疗效与血清IL-1，slL-2R和IFN-γ水平的影响．胃肠病学和肝病学杂志，2002，11(1)：70
43 Jung MC, Page OR. Immunology of hepatitis B infection. Lancet, Infect Dis. 2001, 2:43-50
44 Grob PJ. Hepatitis B: virus, pathogenesis and treatment. Vaccine. 1998, 16:11-16
45 Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 1998, 88:341-350
46 田志刚．NK细胞新理论对重大疾病的新解释．中国免疫学杂志，2002，2：75-79
47 Chen Y, Wei H, Gao B, et al. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepatitis, 2005, 1:34-38
48 Baldus SE, Zirbes TK, Weidner IC, et al. Comparative quantative analasyse of macrophage populations defined by CD68 and carbohydrate antigens in normal and pathologically altered human liver tissue. A nal Cell Pathol, 1998, 16 (3): 141-150
49 Brion CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol, 1999, 17: 189- 220
50 Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000, 192(7):921-930
51 Kimura K, Kakimi K, Wieland S, et al. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol, 2002, 169:5188 -95.
52 Monsalve-De Castillo F, Romero TA, Estevez J, et al. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol. 2002, 9(6):1372-5
53 Victoria JC, Laca GG, Francis VC. Interleukine-12 inhibits hepatitis B virus replication in transgenie mice. J Virol .1997, 71(4):3236- 43
54 Kimura K, Kakimi K, Wieland S, et al. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol. 2002,76 (21): 10702-10707
55 Biron CA. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol. 1997, 9:24-34
56 刘源，韩亚萍，李军，等．慢性乙型肝炎患者外周血淋巴细胞亚群的测定分析．南通医学院学报，2004，24(2)：140-141
57 Vujanovic NL, Polimeno L, Azzarone A, et al. Changes of liver-resident NK cells during liver regeneration in rats. J Immunol. 1995, 154(12): 6324-6338
58 Mackay IR. Hepatoimmunity: a perspective. Immunol Cell Biol. 2002, 80:36-44
59 Norris S, Collins C, Doherty DG, et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol. 1998, 28:84-90
60 张定凤．重新认识乙型肝炎防治中的几个问题．中华医学杂志，2000，80：5-6
61 Xiong, X., Flores, C., Yang, H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine. Hepatology. 1998,28:1669-1673
62 Walter, E., Keist, R., Niederost, B, et al. Hepatitis B virus infection of tupaia hepatoeytes in vitro and in vivo. Hepatology. 1996, 24:1-5
63 Chisari FV, Pinkert CA, Milich DR, et al. A transgenic mouse model of the chronic hepatitis B surface antigen carder state. Science 1985; 230:1157-1160
64 Guidotti, L.G., Matzke, B., Schaller, H., Chisari, F.V. High-level hepatitis B virus replication in transgenic mice. J. Virol. 1995, 69:6158-6169
65 Chisari, F.V. Cytotoxic T Cells and Viral Hepatitis. J. Clin. Invest. 1997,99:1472-1477
66 Morrey, J.D, Sidwell, R.W, Korba, B.A. Animal models for HBV infections-transgenic mice. In: Zak, O., Sande, M. (Eds.), Handbook of Animal Models of Infection. Academic Press, London, 1999:1009-1019
67 Dong Y, Xi H, Yu Y, et al. Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of oxymatrine. J Gastroenterol Hepatol, 2002,17(12): 1299-1306
68 AbeM, Kajino K, Akbar SM, et al. Loss of immunogenecity of liver dendritic cells from mouse with chronic hepatitis. Int J Mol Med, 2002, 9 (1): 71-76
69 屠亚军，祖和，扬鹏，等．人乙型肝炎病毒x基因转基因小鼠模型的建立．中国医学科学院学报，2000，6，22(3)：263-265
70 胡卫江，李建秀，余宏宇，等．乙型肝炎病毒(adr亚型)转基因小鼠的研究．第二军医大学学报，1999，20(4)：212-215
71 熊一力，贾彦征，王洪敏，等．高表达乙型肝炎病毒转基因小鼠的制备．传染病信息，2000，13(4)：164-165
72 刘光泽，熊一力，王洪敏，等．近交系高表达HBV转基因小鼠的建立及表达传代稳定性．中国兽医学报，2003，23(6)：580-582
73 黎怀星，李建秀，杨桦，等．基于PSPORT质粒的转基因小鼠家系的建立．第二军医大学学报，1998，19(1)：9-12
74 卢洋，黎怀星，李建秀，等．基于PMTR1质粒的转基因小鼠突变模型的建立．第二军医大学学报，2000，6(21)：537-540
75 张萍萍，万大方，顾建人，等．抗病毒药物抑制转基因小鼠中HBV的复制．肿瘤，1999，19(6)：356-357
76 雷章恒，李建秀，余宏宇，等．乙型肝炎病毒(ayw亚型)转基因小鼠的建立．第二军医大学学报，1997，18(3)：201-204
77 姚玉成，雷章恒，王忠华，等．乙型肝炎病毒3′末端缺失的presS／S基因在转基因小鼠中的表达．遗传学报，2000，27(11)：941-946
78 熊俊，訾晓渊，姚玉成，等．乙型肝炎病毒x基因转基因小鼠模型的建立及培育．第二军医大学学报，2002，23(11)：1184-1187
79 Hu YP, Hu W J, ZhengWC, et al. Establishment of transgenic mouse harboring hepatitis B virus (adr subtype) genomes. World J Gastroenterol, 2001, 7(1): 111-114
80 訾晓渊，姚玉成，胡以平，等．乙型肝炎转基因小鼠品系C572TgN(HBVadr2.0)的生物学特征．第二军医大学学报，2002，23(11)：1179-1183
81 徐军，訾晓渊，余宏宇．C572TgN(HBVadr2.0)SMMU转基因小鼠肝脏的组织病理学观察．第二军医大学学报，2005，26(3)：283-285
82 Chisari FV, Filipi P, Bunas J, et al. Structural and pathological effect of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc N at 1 Acad Sci. USA, 1987, 84 (19): 6909-6913
83 Chisari FV. Hepatitis B Virus transgenic mice: insights into the virus and the disease. Hepatology, 1995, 22:1316-1325
84 贾彦达，刘光泽，熊一力，等．高表达乙型肝炎病毒转基因小鼠的制备．肝脏，2001，6(增刊)：99
85 刘光泽，熊一力，刘慧萍，等．HBV转基因小鼠脾脏DC的TLR2、TLR9和T细胞Elispot检测分析．中国免疫学杂志．2005，21(5)：367-368
86 Akbar S, M, F,Onp M. Hepatitis B virus(HBV)- transgenic mice as an investigative tool to study immunopathology during HBV infection. Int, J, Path, 1998,79:279-291
87 Wirth S, Guidotti L G, Aado K, et al. Breaking tolerance leads to autoantibody production but not autoimmune disease in HBV envelope transgenic mice. J Immunol, 1995, 154:2504-2515
88 Takachina H, Araki K. Miyazaki, J, et al. Characterization of T-cell tolerance to hepatitis B virus (HBV) transgenic mice. Immunology, 1992, 75(3): 398-405
89 Milich DR. Jones J E. Hughes J L, et al. Is a function of the secreted hepatites B e antigen to induce mmunologic tolerance in utero? Proc Natl Acad Sci. USA, 1990,87 (17): 6599-6603
90 刘光泽，贾彦征，王洪敏，等．HBV转基因小鼠T细胞免疫状态．中国兽医学报，2000，20(4)：356-357
91 任红．张定凤．乙型肝炎患者B细胞分化因子(白细胞介素6)的研究．中华医学杂志，1989，69：264-266
92 李岩，张卓然，杨淑凤，等．Cp G-ODN增强乙型肝炎病毒转基因小鼠对重组乙肝疫苗的细胞免疫应答．大连医科大学学报，2004，26(4)：251-255
93 Kunsc K, Akbar S M, Yamamoto K, et al. Production antibody to hepatitis B surface antigen (anti-HBs) by marine hepatitis B virus neonal tolerance versus antigen presentation by dendritic cells. Inmmology,1997, 92(4):494
94 郑曲波，张宜俊，刘慧萍，等．慢性HBV感染者外周树突状细胞和T细胞体外应答功能的检测和分析．上海医学检验杂志，2003，18(2)：8
95 熊一力，刘光泽，贾彦征．HBV转基因小鼠免疫耐受机制的实验研究．世界华人消化杂志，2002，10(6)：642-645
96 Cavanaugh, V.J., Guidotti, L.G., Chisari, F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 1997,71:3236-3243
97 Morrey, J.D., Bailey, K.W., Korba, B.E, et al. Utilization oftransgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine.Antiviral Res. 1999,42:97-108
98 Morrey, J.D., Korba, B.E., Sidwell, R.W. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection. Antivir. Ther, 1999, (Suppl. 3): 59-68
99 Kajino, K., Kamiya, N., Yayasa, S, et al. Evaluation of anti-hepatitis B virus (HBV) drugs using the HBV transgenic mouse: application of the semiquantitative polymerase chain reaction (PCR) for serum HBV DNA to monitor the drug efficacy. Biochem. Biophys. Res. Commun. 1997, 241:43-48
100 Justin G. Julander, Robert W. Sidwell, John D. Money. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Research. 2002, 55:27-40
101 童光东，周大桥，刘惠玲，等．加味四逆散抑制HBV转基因小鼠HBV实验研究．中西医结合肝病杂志2004，14(2)：85-88
102 李声方，王兮，桂希恩，等．当归多糖对乙肝病毒转基因小鼠树突状细胞功能状态的影响．实用诊断与治疗杂志，2005，19(5)：313-317
103 梁亮．乙型肝炎相关动物模型的研究进展．中国人兽共患病杂志，2005，21(3)：259
104 陈建，赵卫东，王敏，等．乙醇对乙型肝炎病毒转基因小鼠病毒复制和基因表达的影响．中华肝脏病杂志，2005，13(6)：471-472
105 M. Dandri, T.K. Volz, M. Ltitgehetmarm, J. Petersen.Animal models for the study of HBV replication and its variants. Journal of Clinical Virology 34 Suppl. 1. 2005:54-62
106 Raney, A.K., Eggers, C.M., Kline, E.F., Guidotti, L.G, et al. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. J. Virol. 2001,75:2900-2911
107 Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002, 347(3): 168-174
108 Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005, 54(11): 1610-1614
109 拉米夫定临床应用专家组．2004年拉米夫定临床应用专家共识．中华肝脏病杂志，2004，12(7)：425-428
110 Perillo RP. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis. 2005, 25 (Suppl 1):20-28
111 Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat. 2005, 12:333-345
112 Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Inter Med. 1993, 119:312-323
113 Perry CM, Jarvis B. Peginterferon-alpha-2a (40kD): a review of its use in the management of chronic hepatitis C. Drugs, 2001,61: 2263-2288
114 Modi MW, Fultion JS, Buckmann DK, et al.Clearance of pegylated (40kD) interferon-alpha-2a is primarily hepatic. Hepatology, 2000, 32(4 pt 2):371
115 Janssen HLA, van Zonneveld M, Senturk H, et al. for the HBV 99-01 Study Group. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet. 2005,365: 123-129
116 Chun Tao Wai, Anna S.F. Lok. Treatment of hepatitis B.J Gastroenterol. 2002, 37:771-778
117 Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol. 2003, 39: S93-S98
118 Lai CL, Chien RN, Leung NWY, et al. for the asia hepatitis lamivudine study group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998, 339: 61-68
119 Liaw YF, Leung NWY, Chang TT, et al. for the asia hepatitis lamivudine study group. Effects of Extended Lamivudine Therapy in Asian Patients With Chronic Hepatitis B.Gastroenterology.2000,119: 172-180
120 Lok ASF, McMahon BJ. Practice Guidelines Committee, American Association for the Study of the Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004, 39: 857-861
121 EASL Jury EASL International Consensus Conference on Hepatitis B: 2003: 13-14
122 Perrillo R, Harm HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004, 126: 81-90
123 Tassopoulos NC, Volpes R, Pastore G, et al. Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen- negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology. 1999,29: 889-896
124 Perrillo RP, Wright T, Rakela J, et al. A multicenter United States - Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001, 33: 424-432
125 Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000,31: 207-210
126 Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel antihuman immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997, 176:1517-1523
127 Gilson RJ, Chopra K, Murray-Lyon I, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (BIS-POM PMEA) in patients with chronic hepatitis B infection (abstract). Hepatology 1996, 24:281
128 One-Nita SK, Kato N, Shiratori Y, et al.Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999, 103:1635-1640
129 Holy A, Votruba I, Merta A, Cerny J, Vesely J, Vlach J, et al. Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res 1990, 13: 295-311
130 张春平. 阿德福韦二匹伏酯治疗HbeAg阴性(阳性)慢性乙型肝炎.国外医学 . 内科学分册,2004,31(1): 38-39
131 Patrick M, Ting TC, Seng GL, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Mend, 2003,348:808-816
132 Geoffrey Dusheiko.Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies. Journal of Hepatology 2003, 39: S116-S123
133 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CJ for the Adefovir Dipivoxil 438 Study Group. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B. N Engl J Med. 2003,348: 800-807
134 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL. for the Adefovir Dipivoxil 438 Study Group. Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. N Engl J Med, 2005, 352(26): 2673-2681
135 Marion P, Harm H W, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) Suppress YMDD mutant hepatitis B virus replication:48 week preliminary analysis. Hepatology, 2002,36 : 374
136 Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003, 38: 1419-1427
137 Mailliard ME, Gollan JL. Suppressing hepatitis B without resistance - so far, so good. N Engl J Med, 2003, 348: 848-850
138 Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin Liver Dis. 2002,22( Suppl 1):23-31
139 Yang H, Westland CE, Delaney WE, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 2002, 36: 464-473
140 Seifer M, Hamatake RK, Colonno RJ, et al . In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother, 1998 ,42(12): 3200-3208
141 Ono SK, Kato N , Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin invest, 2001, 107 (4): 449-455
142 Chang TT, Chao YC. Sustained response off - treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside - naive, HBeAg (+) patients: 24 - week follow-up results of phase 3 study-022.15 th Asian Pacific Association for the Study of the Liver, 2005: 191
143 ChingLL. Entecavir as first line treatment for CHB: Pro &Cons.15 th Asian Pacific Association for the Study of the Liver August 18-21,2005:41
144 Yao GB, Zhou XQ, Xu DZ, et al. A randomized, p lacebo - controlled study (etv- 056) in china of the efficacy and safety of entecavir ( ETV) in chronic hep tatitis B ( CHB ) patients who have lamivudine (LVD) therapy. 15th Asian Pacific Association for the Study of the Liver, 2005: 203
145 Lai CL. Entecavir is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine- refractory patients. 55th Annual Meeting of the American Society for the Study of Liver Diseases,Boston, 2004
146 Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351(15): 1521-1531
147 Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126(7): 1750-1758
148 Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. Antiviral Res 2004; 64(1): 1-15
149 Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36(6): 687-696
150 Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a (40KD) (PEGASYS) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. N Engl J Med. 2005,352:2682-2694
151 Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004;351(12):1206-1217
152 Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest, 1998,102:968-75
153 Boni C, Penna A, Bertoletti A, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003,39:595-605
154 Lau GK, Cooksley H, Ribiero RM, et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg (+) chronic hepatitis B: efficacy and mechanisms of treatment response. Hepatology. 2004,40(Suppl 1):666A
155 谭青蓝．中医对乙型肝炎证治规律的认识．中华医药卫生杂志2004，1(3)：41-42
156 马克明．扶正祛邪法辨证治疗乙型肝炎150例．新中医，1996，28(9)：46-47
157 张建国．补法在慢性乙型肝炎治疗中的应用．上海中医药杂志，2000，34(4)：28-29
158 李秀惠．疏肝健脾方治疗慢性乙型肝炎临床观察．北京中医，2001，(4)：7-8
159 杨兴中，刘伟英．慢性乙型肝炎中医辨证分型与客观检测指标关系的探讨，山西中医，1991，7(2)：9-11
160 李均．慢性病毒性肝炎279例病理诊断与中医证型的关系．中西医结合肝病杂志，1999，9(1)：10-11
161 邱志济，邱江东，周建中．中医治疗乙肝的新思路和特色．辽宁中医杂志，1998，25(6)：262-263
162 刘士敬．乙型肝炎防治．北京：金盾出版社，2001：33
163 郭一民，古容芳，曾伟刚，等．温阳活血化痰法治疗慢性乙型病毒性肝炎临床观察．井冈山学院学报(自然科学)，2005，26(20：126-128
164 中国中医药学会内科肝病专业委员会．病毒性肝炎中医疗效判定标准(试行)．中医杂志，1992，33(6)：53
165 苏布勒巴图．中医中药分型论治慢性乙型肝炎68例．时珍国医国药2002，13(4)：228
166 黄贤樟．乙型肝炎的中医证治规律探讨．新中医，2001，33(1)：8-9
167 杨健芳，吴轰．保元汤对慢性乙型肝炎患者免疫调节的作用．湖南医科大学学报，1998，(3)：252-254
168 崔丽安，温玉焕，张俊富，等．慢性肝炎患者中医辨证分型与外周血T淋巴细胞亚群及SIL-2R的关系．中医杂志，1998，(8)：488-489
169 张剑，许晓东．慢性乙肝免疫状态与中医辨证关系研究．浙江中医杂志，1998：444
170 高媛，许晓东．慢性乙型肝炎免疫状态与辨证分型的关系．北京中医药大学学报，2002，25(1)：71-72
171 周永禄，李秀婵，李世法．复方乙肝口服液对肝损伤保护作用及其对免疫功能的影响．中药药理与临床，2000，16(4)：34-36
172 于培龙，曾惜秋．归脾汤对慢性肝炎免疫调节作用的评价．牡丹江医学院学报，2001，22(2)：40-42
173 李筠，刘士敬，王小明．中药抗病毒Ⅰ号方治疗慢性乙型肝炎39例．世界华人消化杂志，2001，9(5)：605-607
174 陈浩坤，刘海肃，朱其守，等．治肝灵冲剂治疗慢性乙型肝炎临床研究．现代中西医结合杂志，2000，9(20)：1987．
175 吴建成，范宗滂，朱翔，等．中药补肾方在体外对慢乙肝患者外周血T淋巴细胞亚群的影响．苏州医学院学报，2001，21(3)：30
176 张玮，王育群，秦志丰，等．芪黄冲剂对慢性乙型肝炎患者免疫功能的影响．中西医结合肝病杂志，2000，10(5)：1-2
177 何妙婵，郑其进．赤白桃虎汤治疗慢性丙型肝炎27例临床疗效观察．新中医，1996，28(9)：4748
178 薛霁，曹毅荣，刘丽敏．中医药治疗慢性乙型肝炎的思路浅探．新中医，2003，35(6)：8-9
179 罗日永，何钜楠．健脾补肾法治疗乙肝e抗原阳性95例临床观察．广州中医药大学学报，1996，13(3、4)：21-23
180 连粤，吴婉芬．治疗慢性重型肝炎的临床研究．中西医结合肝病杂志，1999，9(4)：12-15
181 温绍昌，杨思俊，苏国缘．右归饮对慢性乙型肝炎患者外周血T淋巴细胞亚群的影响．中华传染病杂志，1999，(3)：205
182 何浩，张玉亮．打破乙肝病毒免疫耐受的中医药对策．新中医，2000，32(10)：56
183 徐冰．中医药在慢性乙型肝炎治疗中的免疫调节作用．河南中医，2004，24(4)：83-85
184 金介望．中医治疗慢性活动性乙型肝炎的临床观察．中西医结合杂志，1985，(6)：353
185 任豪．四逆散合五苓散加减治疗急性黄疸型肝炎20例，湖北中医，1992，14(5)：55
186 程润泉．四逆散临床应用三则．四川中医，1986，4(8)：131
187 陈继明．慢性肝炎辨治一得．中医杂志，1986，27(3)：13-15
188 蒲青海．黄疸肝炎临证十二法．四川中医，1986，4(8)：201
189 胡晨霞．四逆散的药理与临床研究进展．中国中医药信息杂志，2001，8(增刊)：18
190 Jiang J, Zhou C, Xu Q. Alleviating effects of Si-Ni-San, a traditional Chinese prescription, on experimental liver injury and its mechanisms. Biol Pharm Bull, 2003, 26(8): 1089-1094
191 蒋洁云，徐强．四逆散及其各组成中药对实验性肝损伤的影响．中国天然药物，2004，2(1)：45-49
192 魏伟，刘家骏，刘家琴，等．白芍总苷对乙型肝炎的治疗作用及其前景．中国药理学通 报，2000，16(5)：596-597
193 温树德，吕鲁，范俊珊，等．几种中药的免疫药理及其对乙肝的治疗．医学研究通讯，1997，26(8)：31
194 周金黄．中药药理与临床研究进展．北京：中国科学技术出版社．1992：246
195 常永玲，刘振兰，石秀荣．强力宁治疗慢性活动性肝炎90例临床观察．吉林医学，1993，14(5)：299
196 雨谷．从药理和药化探讨小柴胡汤(三)．国外医学·中医中药分册，1990，12(4)：28
197 陈泽雄，张诗军，罗致强，等．小柴胡汤对慢性乙肝免疫调节及症状的作用．实用中西医结合杂志，1996，9(10)：597
198 刘中景，柳盛，袁有斌．加味小柴胡汤对慢性乙型肝炎患者的免疫调节作用．中国中医药科技，2002，9(4)：234
199 张希东，于清欣，刘中景．拉米夫定联合小柴胡汤抗HBV及调节免疫的临床观察．中西医结合肝病杂志，2004，14(3)：170-171
200 张喜顺．健脾补肾治疗乙肝体会．中国医药论坛，2004，2(10)：84-85
201 王泽荣，吴建成．中药补肾方在体外对乙肝患者外周血淋巴细胞亚群及TNF-α的调节作用．苏州大学学报(医学版)，2003；23(3)：304-306
202 周飞，王灵台，陈建杰，等．拉米夫定和补肾方联合应用治疗慢性乙型肝炎的疗效及对YMDD区域的影响．中国中西医结合杂志，2003，23(6)：417-420
203 Yang PL, Althage A, Chung J, et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. PNAS, 2002, 99(21): 13825
204 徐克成．慢性乙型肝炎的治疗：进展、问题和对策．胃肠病变，2004，9(3)：186-190
205 蒋森，贾静鹏，蒋芳莉．中西医结合治疗慢性乙型肝炎思路与方法探讨．山西中医，2002，18(3)：43-45
206 张宜俊．慢性乙型肝炎抗病毒治疗的浅见．传染病学信息，2002，15(3)：102
207 陈诗慧，郭卫真，刘妮，等．加味四逆散体外抗乙型肝炎病毒的实验研究．中医药学刊，2006，24(3)：478-479
208 陈诗慧，郭卫真，周红燕，等．四逆散体内抗鸭乙型肝炎病毒的实验研究．国际医药卫生导报，2005，11(22)：6-7
209 易学瑞，曾滢，祖萍，等．基因重组(酵母)乙肝疫苗对HBV转基因小鼠细胞免疫调节作用．上海实验动物科学，2003，23(2)：151-153
210 中华医学会传染病与寄生虫病学分会、肝病学分会．病毒性肝炎防治方案．中华肝脏病杂志，2000，8(6)：324-329
211 郑莜萸主编．中药新药临床研究指导原则(试行)．中国医药科技出版社．北京：2002．5．第1版：371-372
212 中华全国中医学会内科肝病专业委员会．病毒性肝炎中医辨证标准(试行)．中医杂 志，1995(5)：39-40
213 程相岭，王兴明．中医辨证调节免疫治疗急慢性乙型肝炎探讨．中西医结合肝病杂志，2002，12(6)：361-361
214 王钦和，李孝保，许成勇．补脾肾、祛湿热、理气血法治疗慢性乙型肝炎．光明中医，2005，20(2)：37-38
215 肖和杰，刘霞，石次国，等．复方淫羊藿治疗慢性乙型肝炎84例．中西医结合肝病杂志，1994，4(增刊)：70-71
216 方曼倩，张友祥，张佳发．中西医结合治疗慢性乙型肝炎的近期疗效观察．中国中医药信息杂志，2001，8(10)：59
217 王严冬．中西医结合治疗慢性乙型肝炎32例疗效观察．河南中医药学刊，2002，17(3)：38-39
218 张建军，王洪京，张红．叶下珠合剂与拉米夫定联合治疗慢性乙型肝炎40例．山东中医药大学学报，2001，25(6)：438
219 陈立华．中医中药治疗病毒性肝炎的疗效．中医杂志，1995，36(10)：621-623
220 C.L. Lai, V. Ratziu, M.F. Yuen,, et al. Viral hepatitis B, Lancet. 2003,362:2089-2094
221 A.K. Raney, R.K. Hamatake, Z. Hong, Agents in clinical development for the treatment of chronic hepatitis B, Expert Opin. Investig. Drugs, 2003, 12:1281-1295
222 刘克洲．中西医结合治疗慢性乙型病毒性肝炎—抗病毒治疗是关键．浙江中西医结合杂志，2005，15(1)：1-3
223 A. M. Rivkin. Adefovir dipivoxil in the treatment of chronic hepatitis B, Ann. Pharmacother. 2004, (38): 625-633
224 D. Sprengers, H. L. Janssen. Immunomodulatory therapy for chronic hepatitis B virus infection, Fundam. Clin. Pharmacol, 2005, 19:17-26
225 王灵台．中西医结合肝病科研的思路与方法．中西医结合肝病杂志，1999，9(3)：1-2
226 姚集鲁．主编．传染病学临床专论．广州：广州高等教育出版社．2002．2
227 陈诗慧，卢焯明．中药治疗乙型病毒性肝炎的进展．中国热带医学，2004，4(1)：137-138
228 赵英杰，范希成．慢性乙型肝炎抗病毒治疗的进展．寄生虫病与感染性疾病，2003，2(1)：34-37
229 张定风．乙型肝炎的发病机理及临床：免疫调节系统的功能．重庆：重庆出版社，1992：151-167
230 张盛杰，陈建杰，奚骏，等．补肾冲剂治疗慢性乙型肝炎32例．中西医结合肝病杂志，2005，15(6)：366
231 高月求，孙学华，章晓鹰，等．补肾方对慢性乙型肝炎T细胞亚群及其功能的影响．中国中西医结合杂志，2005，25(5)：408-411
232 王培兴．疏肝健脾补肾法对乙肝的防治．光明中医，2006，21(1)：61-62
233 李乐，蔡鹏威，伍严安，等．慢性乙肝病毒携带者的细胞免疫功能变化及其与血清HBVDNA的关系．福建医药杂志，2003，25(6)：18-21
234 叶维法，钟振义．肝病免疫学：细胞免疫的病理作用．天津：天津科学技术出版社，1997．109-118
235 吴成．慢性乙型肝炎的中医药实验研究评析．中医药学刊，2002，20(1)：56-58
236 徐春军．乙肝病毒基因变异与中医药治疗策略探讨．中国中医药信息杂志，2002，9(11)：24-25
237 高月求，王灵台，陈建杰．补肾冲剂治疗慢性乙型肝炎的临床研究．上海中医药大学学报，2001，15(1)：34-36
238 李东复，闫峻，周晓琦，等．慢性肝病患者T淋巴细胞亚群、IL-10和IL-12变化的意义．吉林大学学报(医学版)，2004，30(4)：583-585
239 杨宏志，边壮，王拥泽，等．慢性乙型肝炎虚实病机与病毒复制及T细胞关系的研究．中国中西医结合急救杂志，2003，10(3)：158-160
240 B. Rehermann, C. Pasquinelli, S.M. Mosier, F.V. Chisari. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection, J. Clin. Invest. 1995, 96: 1527- 1534
241 L.G. Guidotti, T. Ishikawa, M.V. Hobbs, et al. Intracellular inactivation of the hepatitis B vires by cytotoxic T lymphocytes, Immunity. 1996, 4:25-36
242 L.G. Guidotti, K. Ando, M.V. Hobbs, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice, Proc. Natl. Acad. Sci. U. S. A. 1994, 91: 3764- 3768
243 陈智．慢性乙型肝炎治疗的若干研究进展．浙江大学学报(医学版)，2005，34(2)：95-97
244 Guo JT, Zhou H, Liu C, et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000, 74:1495-1505
245 Mosmann T. Rapid colorimetric assay for cellar growth and survival application to proliferation and cytotoxicity assays. J Immunol Methods, 1983,65:55
246 张跃新，傅希贤，张乃临，等．3种中草药对乙型肝炎病毒复制抑制效果的体外实验研究．新疆医学院学报，1996，19(4)：272-275
247 陈压西，郭树华，齐珍元，等．叶下珠有效部位抗鸭乙型肝炎病毒及体外抗HBV活性的研究．中药药理与临床，1999，15(6)：16-18
248 张振强，王倩嵘．软肝饮对HBV转染细胞表达功能抑制的实验研究．开封医专学报2000，19(1)：42-43
249 Heijtink RA, De Wilde GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res, 1993; 21:141-153
250 张其威，张楚瑜．抗病毒中药研究的最新进展．中成药，2005，27(1)：116-119
251 聂哲云．四逆散加味治疗乙型肝炎99例．恩施医专学报，1994，11(2)：38-40
252 廖云龙，胡志方，徐婉如，等．复方四逆散治疗43例慢性活动性乙型肝炎的临床观察．江西中医学院学报，1996，8(1)：4-5
253 刘星．加味四逆散抗拉米夫定停药后慢性乙型肝炎复发12例．中国中西医结合杂志，2002，22(8)：593
254 任建平，陈蔓芙．茯苓对消化系统疾病影响的研究概述．中国中医药科技，1999，6(1)：63-64
255 蔺学燕，董传海，李伟华．淫羊藿有效成分的药理研究与临床应用．时珍国医国药，2005，16(9)：917-918
256 丁雁，刑善田，周金黄．淫羊藿多糖促进小鼠T和B细胞H-DdR掺入和诱生干扰素作用的研究．中国免疫学杂志，1985，1(6)：42-42
257 丁雁，刑善田，周黄金．淫羊藿多糖致小鼠胸腺缩小的免疫药理研究．中国免疫学杂志，1993，9(3)：185-185
258 丁雁，刑善田，周黄金．淫羊藿多糖和苷的胸腺缩小的免疫药理研究．中国免疫学杂志，1993，9(5)：342-342
259 储岳峰，颜新敏，李祥瑞，等．半定量RT-PCR测定中药成分对小鼠脾T细胞IL-2mRNA水平的影响．中国农业科学，2005，38(9)：1911-1916
260 梅国强．乙型肝炎的中医治疗．北京：科学技术出版社，1995：304-307
261 沈自尹，蔡定芳，张玲娟，等．补肾和健脾对免疫系统不同作用方式的研究．中国中西医结合杂志，1997，17(6)：351
262 白隆华，董青松，蒲瑞翎．中药鸡骨草研究概况．广西农业科学，2005，36(5)：476-478
263 周芳，李爱嫒．鸡骨草与毛鸡骨草抗炎免疫的实验研究．云南中医中药杂志，2005，26(4)：33-34
264 Chon CY, Han KH, Lee KS, et al. Peritoneoscopic liver biopsy findings in asymptomatic chronic HBsAg carriers wit h normal liver function test s and no hepatomegaly. Yonsei Med J, 1996, 37 (5): 295-301.
265 骆抗先，朱幼芙．乙型肝炎：临床与活体组织病理．北京：科学出版社，2001．162-179
266 Chisari FV, Klopchin K. Moriyama T, et al. Molecular pathogenesis of hepatocellular carcionoma in HBV transgenic mice. Cell, 1989, 59:1145
267 Pasquetto V, Wieland S, Chisari FV. Intracellular hepatitis B virus nueleoeapsids survive eytotoxie T-lymphocyte- induced apoptosis. J Virol, 2000, 74:9792-9796
268 Wang KX, Peng JI, Wang XF, et al.Detection of T lymphocyte subsets and mlL-2R on surface of PBMC in patients with hepatitis B. World J Gastroenterol, 2003, 9: 2017-2020
269 Jung MC, Spengler U, Schraut W, et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol. 1991, 13: 310-317
270 Rehermann B, Fowler P, Sidney J, Person J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med. 1995, 181:1047-1058
271 Koziel M J. Cytokines in viral hepatitis. Semin Liver Dis, 1999, 19:157-1699
272 Lau G K. Use of immunomodulatory therapy (other than interfere on) for the treatment of chronic hepatitis B virus infection. J Gastroenterol Hepatol, 2000, 15:46-52
273 黄茵．慢性感染的免疫耐受形成机制．国外医学·流行病学传染病学分册，2001，(2)：57
274 陈亚冈，马亦林，屠中元，等．乙型慢性活动性肝炎患者外周血淋巴细胞亚群及IL-2受体表达．中华传染病杂志，1992，10(1)：48-49
275 万克青，杨旭，郑宣鹤．香茹多糖注射液对慢性活动性肝炎外周血T淋巴细胞亚群和IL-2受体表达作用的研究．中国免疫学杂志，1995，(5)：298
276 毕青，张俊富，温玉焕，等．复方仙灵脾冲剂对慢性乙型肝炎患者slL-2RT淋巴细胞亚群的影响．中西医结合肝病杂志，2000，(1)：14
277 张广业，王育群，张玮．中医药免疫调节治疗慢性乙型病毒性肝炎研究进展．安徽中医临床杂志，2002，14(6)：518-520
278 黄争荣．中药复方对慢性乙型肝炎的免疫调节作用研究进展．福建中医学院学报，2003，13(1)：62-64
279 周春祥，徐强，曹劲松，等．四逆散改善细胞免疫性肝损伤作用机理研究．中国中医基础医学杂志，2002，8(5)：47-49
280 Raney AK, McLachlan A. The biology of hepatitis B virus. Molecular biology of the hepatitis B virus. Boca Raton, FL7 CRC Press; 1991:1-37
281 Babinet C, Farza H, Morello D, et al. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985, 230:1160-1163
282 Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990; 50:3400-3407
283 Lee TH, Finegold MJ, Ring-Fong S, et al. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol 1990, 64:5939-5947
284 Reifenberg K, Lohler J, Pudollek HP, et al. Long-term expression of the hepatitis B virus core-e- and X-protein does not cause pathologic changes in transgenic mice. J Hepatol 1997, 26:119-130
285 Kim CM, Koike K, Salto I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320
286 Chomarat P, Rice JM, Slagle BL, et al. Hepatitis B virusinduced liver injury and altered expression of carcinogen metabolishing enzymes: the role of the HBx protein. Toxicol Lett 1998; 102-103:595-601
287 Yu DY, Moon HB, Son JK, et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999, 31:123-132
288 Penna, A, Del Prete, G., Cavalli, A, et al. Predominant T helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute selflimited hepatitis B. Hepatology. 1997, 25:1022-1027
289 Bertoletti, A, D'Elios, M M, Boni, C, et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology, 1997, 112:193-199
290 Romero, R., and Lavine, J. E. Cytokine inhibition of the hepatitis B virus core promoter. Hepatology, 1996, 23:17-23
291 Guy B, Pascal N, Francon A, et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine, 2001, 19:1794
292 Del Giobbo, Foli A, Balzarini J, et al. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl) adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res. 1991, 16:65-75
293 Cooksley H, Chokshi S, Wedemeyer H, et al. Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: a multicentre, controlled study. J Hepatol. 2002, 36:7
294 周娟，李连闯，毕明刚，等．慢性乙肝的细胞免疫病毒和中药与植物药治疗．国外医药·植物药分册，2006，21(5)：202-206
295 顾缨．中药免疫调节剂治疗乙型病毒性肝炎的研究近况．中医药临床杂志，2005，17(3)：311-312
296 Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol, 2000, 12:403-408
297 Boni C, Penna A, Ogg GS, Bertoletti A, et al. Lamivudine treatment can overcome cytotoxic Tcell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology, 2001, 33:963-971
298 Alexander GJW, Mondelli M, Naumov NN, et al. Functional characterization of peripheral blood lymphocytes inchronic HBsAg carders. Clin Exp Immunl, 1986, 63:498
2 Luo KX, Zhu YF (eds). Hepatitis B: basic biology and clinical science. People's Medical Publishing House, 2001, Beijing
3 姚云清，张定凤．乙型肝炎病毒感染、复制及其清除机制．中华肝脏病杂志，2002，10(5)：398-400
4 李山．HBV感染后的Th1／Th2细胞应答．医学文选，2000，19(5)：752-754
5 刘林华．阿德福韦酯抗乙肝病毒治疗进展．国外医学·病毒学分册，2005，12(5)：154
6 Vingerhoets J, Michielsen P, Vanham G, et al. HBV-specific lymphoproliferative and cytokine responses with chronic hepatitis. J Hepatol, 1998,28:8-16
7 刘光伟．慢性乙型肝炎免疫病理及中医药免疫调节治疗研究概况．上海中医药大学学报，2005，19(1)：59-61
8 Chisari, F.V., Ferrafi, C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995,13:29-60
9 王福生．天然免疫应答清除HBV的作用及其临床免疫治疗的前景．中华医学杂志，2005，85(17)：1158-1159
10 U. Protzer, H. Schaller. Immune Escape by Hepatitis B Viruses. Virus Genes 2000,21:1/2, 27-37,
11 Janeway C.A, Travers P., Immunobiology. The Immune System in Health and Disease. Current Biology Ltd., London, 1998, 9:1-9:46
12 温帆渊．慢性乙型肝炎抗病毒治疗的现状及展望．现代医药卫生，2005，21(10)：1183-1184
13 Rehermann B, NascimbeniM. Immunology of hepatitis B virus and hepatitis C virus infection Nat Rev Immunol, 2005, 5:215-229
14 Guidotti L.G., Rochford R, Chung I, et al. Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection. Science 1999,284: 825-829
15 Yang P M, Pu I J, Lai M Y, et al. Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic type B hepatitis, with special emphasis on the activation status of lymphocytes. AMJ Gastroenterol, 1998, 83: 948-951
16 骆抗生．乙型肝炎基础与临床．北京：人民出版社．第2版，2001：188-189
17 Maini MK, Boni C, Lee CK, et al. The role of virus specific CD8 + cells in liver damage and viral control during persistent hepatitis B virus infection. J Ex p Med, 2000,191(8): 1269-1280
18 Chisafi FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. A m J Pathol, 2000, 156 (4): 1117-1132
19 Ando K, Moriyadma T, Guidotti L G, et al. Mechanisms of class Ⅰ restricted immunopathology. A transgenic mouse model of fulnuinant hepatitis. J Ex p Med, 1993, 178 (5): 1541-1554
20 Gobbold S, Waldmmm H. Infectious Tolerance. Curr Opin Immunol,1999, 10:518-524
21 Kung T. Impaired clonal expansion in athymic nude CD4~+ / CD8~+ T cells. J Immunol, 2001, 140:3727-3729
22 Del-Prete G, Maggi E, Romagnani, S. Human Th1 and Th2 cells: functional properties, mechanisms of regulation, and role in disease. Lad Invest, 1994,70:299-306
23 骆抗先．乙型肝炎的基础和临床．北京：人民卫生出版社．第1版．1997：115-131
24 Mc Farlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother, 1999, 53: 255-263
25 Jens S, Jennifer P, Alexandra K, et al. Silibinin protects mice from T cell-dependent liver injury. J Hepatology, 2003, 39:333-400
26 Mlilich DR. Influence of T-helper cell subsets and cross regulation in hepatitis B virus infection. J Viral Hepat, 1997, 4(suppl 2):48-59
27 Fukuda R, Ishimura N, Nguyen TX, et al. The expression of and IL-2, IL-4 and interferon-gamma(IFN-gamma) mRNA/using liver biopsies at different prases of acute exaceberbation if chronic hepatitis B. Clin Exp Immunol, 1995,100(3):446-451
28 Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001, 19:65-91
29 Nayersina, R., Fowler, P., Guilhot, S, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J. Immunol. 1993, 150:4659—4671
30 Kakimi K, Lane TE, Chisari FV, Guidotti LG. Cutting edge: inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol. 2001, 167:6701-6705
31 Bream JH, Carrington M, O'Toole S, et al. Polymorphisms of the human IFNG gene noneoding regions. Immunogenetics. 2000, 51:50-58
32 Sato S, Kawashing H, Oshiro H, et al. A Virological and immunological outcome with Epstein-Barr virus-associated hemophagocytec syndrome. J Clin Virol.2004, 31:235-238
33 Shao C, Qu J, He l, et al. Transient overexprission of a interferon promotes Aapergillus clerarance in invasive pulmonary aspergillosis. Clin Exp Immunol. 2005, 142:233-241
34 Mizuhara, H, Uno, M, Seki, N, et al. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology, 1996, 23:1608-1615
35 Billiau A, Heremans H, Vermeire K, Matthys P. Immunomodulatory properties of interferon-gamma. An update. Ann N Y Acad Sci. 1998,856:22-23
36 Billiau, A. Interferon-gamma: Biology and role in pathogenesis. Adv. Immunol. 1996, 162:61-130
37 Schultz U, Chisari FV. Recombinant duck interferon gamma inhibits duck hepatitis B virus replication in primary hepatocytes. J Virol, 1999,73:3162-3168
38 Guidotti LG, Matzke B, Chisari FV. Hepatitis B vires replication is cell cycle independent during liver regeneratio in transgenic mice. J Virol, 1997,71:4804-4808
39 Uprichard SL, Wieland SF, Althage A, Chisari FV. Transcriptional and posttranscriptional control of hepatitis Bvirus gene expression. Proc Natl Acad Sci USA. 2003, 100:1310-1315
40 Guidotti LG, McClary H, Loudis JM, et al. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med, 2000,191 : 1247-1252
41 张飚，隋涛，于秀英，等．慢性乙肝患者外周血单个核细胞凋亡及细胞因子检测的意义．临床肝胆病杂志，2004，20(4)：138-140
42 陈焰，田德英．治疗对慢性乙型肝炎抗病毒疗效与血清IL-1，slL-2R和IFN-γ水平的影响．胃肠病学和肝病学杂志，2002，11(1)：70
43 Jung MC, Page OR. Immunology of hepatitis B infection. Lancet, Infect Dis. 2001, 2:43-50
44 Grob PJ. Hepatitis B: virus, pathogenesis and treatment. Vaccine. 1998, 16:11-16
45 Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 1998, 88:341-350
46 田志刚．NK细胞新理论对重大疾病的新解释．中国免疫学杂志，2002，2：75-79
47 Chen Y, Wei H, Gao B, et al. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepatitis, 2005, 1:34-38
48 Baldus SE, Zirbes TK, Weidner IC, et al. Comparative quantative analasyse of macrophage populations defined by CD68 and carbohydrate antigens in normal and pathologically altered human liver tissue. A nal Cell Pathol, 1998, 16 (3): 141-150
49 Brion CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol, 1999, 17: 189- 220
50 Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000, 192(7):921-930
51 Kimura K, Kakimi K, Wieland S, et al. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol, 2002, 169:5188 -95.
52 Monsalve-De Castillo F, Romero TA, Estevez J, et al. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol. 2002, 9(6):1372-5
53 Victoria JC, Laca GG, Francis VC. Interleukine-12 inhibits hepatitis B virus replication in transgenie mice. J Virol .1997, 71(4):3236- 43
54 Kimura K, Kakimi K, Wieland S, et al. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol. 2002,76 (21): 10702-10707
55 Biron CA. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol. 1997, 9:24-34
56 刘源，韩亚萍，李军，等．慢性乙型肝炎患者外周血淋巴细胞亚群的测定分析．南通医学院学报，2004，24(2)：140-141
57 Vujanovic NL, Polimeno L, Azzarone A, et al. Changes of liver-resident NK cells during liver regeneration in rats. J Immunol. 1995, 154(12): 6324-6338
58 Mackay IR. Hepatoimmunity: a perspective. Immunol Cell Biol. 2002, 80:36-44
59 Norris S, Collins C, Doherty DG, et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol. 1998, 28:84-90
60 张定凤．重新认识乙型肝炎防治中的几个问题．中华医学杂志，2000，80：5-6
61 Xiong, X., Flores, C., Yang, H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine. Hepatology. 1998,28:1669-1673
62 Walter, E., Keist, R., Niederost, B, et al. Hepatitis B virus infection of tupaia hepatoeytes in vitro and in vivo. Hepatology. 1996, 24:1-5
63 Chisari FV, Pinkert CA, Milich DR, et al. A transgenic mouse model of the chronic hepatitis B surface antigen carder state. Science 1985; 230:1157-1160
64 Guidotti, L.G., Matzke, B., Schaller, H., Chisari, F.V. High-level hepatitis B virus replication in transgenic mice. J. Virol. 1995, 69:6158-6169
65 Chisari, F.V. Cytotoxic T Cells and Viral Hepatitis. J. Clin. Invest. 1997,99:1472-1477
66 Morrey, J.D, Sidwell, R.W, Korba, B.A. Animal models for HBV infections-transgenic mice. In: Zak, O., Sande, M. (Eds.), Handbook of Animal Models of Infection. Academic Press, London, 1999:1009-1019
67 Dong Y, Xi H, Yu Y, et al. Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of oxymatrine. J Gastroenterol Hepatol, 2002,17(12): 1299-1306
68 AbeM, Kajino K, Akbar SM, et al. Loss of immunogenecity of liver dendritic cells from mouse with chronic hepatitis. Int J Mol Med, 2002, 9 (1): 71-76
69 屠亚军，祖和，扬鹏，等．人乙型肝炎病毒x基因转基因小鼠模型的建立．中国医学科学院学报，2000，6，22(3)：263-265
70 胡卫江，李建秀，余宏宇，等．乙型肝炎病毒(adr亚型)转基因小鼠的研究．第二军医大学学报，1999，20(4)：212-215
71 熊一力，贾彦征，王洪敏，等．高表达乙型肝炎病毒转基因小鼠的制备．传染病信息，2000，13(4)：164-165
72 刘光泽，熊一力，王洪敏，等．近交系高表达HBV转基因小鼠的建立及表达传代稳定性．中国兽医学报，2003，23(6)：580-582
73 黎怀星，李建秀，杨桦，等．基于PSPORT质粒的转基因小鼠家系的建立．第二军医大学学报，1998，19(1)：9-12
74 卢洋，黎怀星，李建秀，等．基于PMTR1质粒的转基因小鼠突变模型的建立．第二军医大学学报，2000，6(21)：537-540
75 张萍萍，万大方，顾建人，等．抗病毒药物抑制转基因小鼠中HBV的复制．肿瘤，1999，19(6)：356-357
76 雷章恒，李建秀，余宏宇，等．乙型肝炎病毒(ayw亚型)转基因小鼠的建立．第二军医大学学报，1997，18(3)：201-204
77 姚玉成，雷章恒，王忠华，等．乙型肝炎病毒3′末端缺失的presS／S基因在转基因小鼠中的表达．遗传学报，2000，27(11)：941-946
78 熊俊，訾晓渊，姚玉成，等．乙型肝炎病毒x基因转基因小鼠模型的建立及培育．第二军医大学学报，2002，23(11)：1184-1187
79 Hu YP, Hu W J, ZhengWC, et al. Establishment of transgenic mouse harboring hepatitis B virus (adr subtype) genomes. World J Gastroenterol, 2001, 7(1): 111-114
80 訾晓渊，姚玉成，胡以平，等．乙型肝炎转基因小鼠品系C572TgN(HBVadr2.0)的生物学特征．第二军医大学学报，2002，23(11)：1179-1183
81 徐军，訾晓渊，余宏宇．C572TgN(HBVadr2.0)SMMU转基因小鼠肝脏的组织病理学观察．第二军医大学学报，2005，26(3)：283-285
82 Chisari FV, Filipi P, Bunas J, et al. Structural and pathological effect of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc N at 1 Acad Sci. USA, 1987, 84 (19): 6909-6913
83 Chisari FV. Hepatitis B Virus transgenic mice: insights into the virus and the disease. Hepatology, 1995, 22:1316-1325
84 贾彦达，刘光泽，熊一力，等．高表达乙型肝炎病毒转基因小鼠的制备．肝脏，2001，6(增刊)：99
85 刘光泽，熊一力，刘慧萍，等．HBV转基因小鼠脾脏DC的TLR2、TLR9和T细胞Elispot检测分析．中国免疫学杂志．2005，21(5)：367-368
86 Akbar S, M, F,Onp M. Hepatitis B virus(HBV)- transgenic mice as an investigative tool to study immunopathology during HBV infection. Int, J, Path, 1998,79:279-291
87 Wirth S, Guidotti L G, Aado K, et al. Breaking tolerance leads to autoantibody production but not autoimmune disease in HBV envelope transgenic mice. J Immunol, 1995, 154:2504-2515
88 Takachina H, Araki K. Miyazaki, J, et al. Characterization of T-cell tolerance to hepatitis B virus (HBV) transgenic mice. Immunology, 1992, 75(3): 398-405
89 Milich DR. Jones J E. Hughes J L, et al. Is a function of the secreted hepatites B e antigen to induce mmunologic tolerance in utero? Proc Natl Acad Sci. USA, 1990,87 (17): 6599-6603
90 刘光泽，贾彦征，王洪敏，等．HBV转基因小鼠T细胞免疫状态．中国兽医学报，2000，20(4)：356-357
91 任红．张定凤．乙型肝炎患者B细胞分化因子(白细胞介素6)的研究．中华医学杂志，1989，69：264-266
92 李岩，张卓然，杨淑凤，等．Cp G-ODN增强乙型肝炎病毒转基因小鼠对重组乙肝疫苗的细胞免疫应答．大连医科大学学报，2004，26(4)：251-255
93 Kunsc K, Akbar S M, Yamamoto K, et al. Production antibody to hepatitis B surface antigen (anti-HBs) by marine hepatitis B virus neonal tolerance versus antigen presentation by dendritic cells. Inmmology,1997, 92(4):494
94 郑曲波，张宜俊，刘慧萍，等．慢性HBV感染者外周树突状细胞和T细胞体外应答功能的检测和分析．上海医学检验杂志，2003，18(2)：8
95 熊一力，刘光泽，贾彦征．HBV转基因小鼠免疫耐受机制的实验研究．世界华人消化杂志，2002，10(6)：642-645
96 Cavanaugh, V.J., Guidotti, L.G., Chisari, F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 1997,71:3236-3243
97 Morrey, J.D., Bailey, K.W., Korba, B.E, et al. Utilization oftransgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine.Antiviral Res. 1999,42:97-108
98 Morrey, J.D., Korba, B.E., Sidwell, R.W. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection. Antivir. Ther, 1999, (Suppl. 3): 59-68
99 Kajino, K., Kamiya, N., Yayasa, S, et al. Evaluation of anti-hepatitis B virus (HBV) drugs using the HBV transgenic mouse: application of the semiquantitative polymerase chain reaction (PCR) for serum HBV DNA to monitor the drug efficacy. Biochem. Biophys. Res. Commun. 1997, 241:43-48
100 Justin G. Julander, Robert W. Sidwell, John D. Money. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Research. 2002, 55:27-40
101 童光东，周大桥，刘惠玲，等．加味四逆散抑制HBV转基因小鼠HBV实验研究．中西医结合肝病杂志2004，14(2)：85-88
102 李声方，王兮，桂希恩，等．当归多糖对乙肝病毒转基因小鼠树突状细胞功能状态的影响．实用诊断与治疗杂志，2005，19(5)：313-317
103 梁亮．乙型肝炎相关动物模型的研究进展．中国人兽共患病杂志，2005，21(3)：259
104 陈建，赵卫东，王敏，等．乙醇对乙型肝炎病毒转基因小鼠病毒复制和基因表达的影响．中华肝脏病杂志，2005，13(6)：471-472
105 M. Dandri, T.K. Volz, M. Ltitgehetmarm, J. Petersen.Animal models for the study of HBV replication and its variants. Journal of Clinical Virology 34 Suppl. 1. 2005:54-62
106 Raney, A.K., Eggers, C.M., Kline, E.F., Guidotti, L.G, et al. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. J. Virol. 2001,75:2900-2911
107 Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002, 347(3): 168-174
108 Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005, 54(11): 1610-1614
109 拉米夫定临床应用专家组．2004年拉米夫定临床应用专家共识．中华肝脏病杂志，2004，12(7)：425-428
110 Perillo RP. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis. 2005, 25 (Suppl 1):20-28
111 Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat. 2005, 12:333-345
112 Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Inter Med. 1993, 119:312-323
113 Perry CM, Jarvis B. Peginterferon-alpha-2a (40kD): a review of its use in the management of chronic hepatitis C. Drugs, 2001,61: 2263-2288
114 Modi MW, Fultion JS, Buckmann DK, et al.Clearance of pegylated (40kD) interferon-alpha-2a is primarily hepatic. Hepatology, 2000, 32(4 pt 2):371
115 Janssen HLA, van Zonneveld M, Senturk H, et al. for the HBV 99-01 Study Group. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet. 2005,365: 123-129
116 Chun Tao Wai, Anna S.F. Lok. Treatment of hepatitis B.J Gastroenterol. 2002, 37:771-778
117 Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol. 2003, 39: S93-S98
118 Lai CL, Chien RN, Leung NWY, et al. for the asia hepatitis lamivudine study group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998, 339: 61-68
119 Liaw YF, Leung NWY, Chang TT, et al. for the asia hepatitis lamivudine study group. Effects of Extended Lamivudine Therapy in Asian Patients With Chronic Hepatitis B.Gastroenterology.2000,119: 172-180
120 Lok ASF, McMahon BJ. Practice Guidelines Committee, American Association for the Study of the Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004, 39: 857-861
121 EASL Jury EASL International Consensus Conference on Hepatitis B: 2003: 13-14
122 Perrillo R, Harm HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004, 126: 81-90
123 Tassopoulos NC, Volpes R, Pastore G, et al. Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen- negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology. 1999,29: 889-896
124 Perrillo RP, Wright T, Rakela J, et al. A multicenter United States - Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001, 33: 424-432
125 Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000,31: 207-210
126 Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel antihuman immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997, 176:1517-1523
127 Gilson RJ, Chopra K, Murray-Lyon I, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (BIS-POM PMEA) in patients with chronic hepatitis B infection (abstract). Hepatology 1996, 24:281
128 One-Nita SK, Kato N, Shiratori Y, et al.Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999, 103:1635-1640
129 Holy A, Votruba I, Merta A, Cerny J, Vesely J, Vlach J, et al. Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res 1990, 13: 295-311
130 张春平. 阿德福韦二匹伏酯治疗HbeAg阴性(阳性)慢性乙型肝炎.国外医学 . 内科学分册,2004,31(1): 38-39
131 Patrick M, Ting TC, Seng GL, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Mend, 2003,348:808-816
132 Geoffrey Dusheiko.Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies. Journal of Hepatology 2003, 39: S116-S123
133 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CJ for the Adefovir Dipivoxil 438 Study Group. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B. N Engl J Med. 2003,348: 800-807
134 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL. for the Adefovir Dipivoxil 438 Study Group. Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. N Engl J Med, 2005, 352(26): 2673-2681
135 Marion P, Harm H W, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) Suppress YMDD mutant hepatitis B virus replication:48 week preliminary analysis. Hepatology, 2002,36 : 374
136 Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003, 38: 1419-1427
137 Mailliard ME, Gollan JL. Suppressing hepatitis B without resistance - so far, so good. N Engl J Med, 2003, 348: 848-850
138 Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin Liver Dis. 2002,22( Suppl 1):23-31
139 Yang H, Westland CE, Delaney WE, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 2002, 36: 464-473
140 Seifer M, Hamatake RK, Colonno RJ, et al . In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother, 1998 ,42(12): 3200-3208
141 Ono SK, Kato N , Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin invest, 2001, 107 (4): 449-455
142 Chang TT, Chao YC. Sustained response off - treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside - naive, HBeAg (+) patients: 24 - week follow-up results of phase 3 study-022.15 th Asian Pacific Association for the Study of the Liver, 2005: 191
143 ChingLL. Entecavir as first line treatment for CHB: Pro &Cons.15 th Asian Pacific Association for the Study of the Liver August 18-21,2005:41
144 Yao GB, Zhou XQ, Xu DZ, et al. A randomized, p lacebo - controlled study (etv- 056) in china of the efficacy and safety of entecavir ( ETV) in chronic hep tatitis B ( CHB ) patients who have lamivudine (LVD) therapy. 15th Asian Pacific Association for the Study of the Liver, 2005: 203
145 Lai CL. Entecavir is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine- refractory patients. 55th Annual Meeting of the American Society for the Study of Liver Diseases,Boston, 2004
146 Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351(15): 1521-1531
147 Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126(7): 1750-1758
148 Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. Antiviral Res 2004; 64(1): 1-15
149 Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36(6): 687-696
150 Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a (40KD) (PEGASYS) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. N Engl J Med. 2005,352:2682-2694
151 Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004;351(12):1206-1217
152 Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest, 1998,102:968-75
153 Boni C, Penna A, Bertoletti A, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003,39:595-605
154 Lau GK, Cooksley H, Ribiero RM, et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg (+) chronic hepatitis B: efficacy and mechanisms of treatment response. Hepatology. 2004,40(Suppl 1):666A
155 谭青蓝．中医对乙型肝炎证治规律的认识．中华医药卫生杂志2004，1(3)：41-42
156 马克明．扶正祛邪法辨证治疗乙型肝炎150例．新中医，1996，28(9)：46-47
157 张建国．补法在慢性乙型肝炎治疗中的应用．上海中医药杂志，2000，34(4)：28-29
158 李秀惠．疏肝健脾方治疗慢性乙型肝炎临床观察．北京中医，2001，(4)：7-8
159 杨兴中，刘伟英．慢性乙型肝炎中医辨证分型与客观检测指标关系的探讨，山西中医，1991，7(2)：9-11
160 李均．慢性病毒性肝炎279例病理诊断与中医证型的关系．中西医结合肝病杂志，1999，9(1)：10-11
161 邱志济，邱江东，周建中．中医治疗乙肝的新思路和特色．辽宁中医杂志，1998，25(6)：262-263
162 刘士敬．乙型肝炎防治．北京：金盾出版社，2001：33
163 郭一民，古容芳，曾伟刚，等．温阳活血化痰法治疗慢性乙型病毒性肝炎临床观察．井冈山学院学报(自然科学)，2005，26(20：126-128
164 中国中医药学会内科肝病专业委员会．病毒性肝炎中医疗效判定标准(试行)．中医杂志，1992，33(6)：53
165 苏布勒巴图．中医中药分型论治慢性乙型肝炎68例．时珍国医国药2002，13(4)：228
166 黄贤樟．乙型肝炎的中医证治规律探讨．新中医，2001，33(1)：8-9
167 杨健芳，吴轰．保元汤对慢性乙型肝炎患者免疫调节的作用．湖南医科大学学报，1998，(3)：252-254
168 崔丽安，温玉焕，张俊富，等．慢性肝炎患者中医辨证分型与外周血T淋巴细胞亚群及SIL-2R的关系．中医杂志，1998，(8)：488-489
169 张剑，许晓东．慢性乙肝免疫状态与中医辨证关系研究．浙江中医杂志，1998：444
170 高媛，许晓东．慢性乙型肝炎免疫状态与辨证分型的关系．北京中医药大学学报，2002，25(1)：71-72
171 周永禄，李秀婵，李世法．复方乙肝口服液对肝损伤保护作用及其对免疫功能的影响．中药药理与临床，2000，16(4)：34-36
172 于培龙，曾惜秋．归脾汤对慢性肝炎免疫调节作用的评价．牡丹江医学院学报，2001，22(2)：40-42
173 李筠，刘士敬，王小明．中药抗病毒Ⅰ号方治疗慢性乙型肝炎39例．世界华人消化杂志，2001，9(5)：605-607
174 陈浩坤，刘海肃，朱其守，等．治肝灵冲剂治疗慢性乙型肝炎临床研究．现代中西医结合杂志，2000，9(20)：1987．
175 吴建成，范宗滂，朱翔，等．中药补肾方在体外对慢乙肝患者外周血T淋巴细胞亚群的影响．苏州医学院学报，2001，21(3)：30
176 张玮，王育群，秦志丰，等．芪黄冲剂对慢性乙型肝炎患者免疫功能的影响．中西医结合肝病杂志，2000，10(5)：1-2
177 何妙婵，郑其进．赤白桃虎汤治疗慢性丙型肝炎27例临床疗效观察．新中医，1996，28(9)：4748
178 薛霁，曹毅荣，刘丽敏．中医药治疗慢性乙型肝炎的思路浅探．新中医，2003，35(6)：8-9
179 罗日永，何钜楠．健脾补肾法治疗乙肝e抗原阳性95例临床观察．广州中医药大学学报，1996，13(3、4)：21-23
180 连粤，吴婉芬．治疗慢性重型肝炎的临床研究．中西医结合肝病杂志，1999，9(4)：12-15
181 温绍昌，杨思俊，苏国缘．右归饮对慢性乙型肝炎患者外周血T淋巴细胞亚群的影响．中华传染病杂志，1999，(3)：205
182 何浩，张玉亮．打破乙肝病毒免疫耐受的中医药对策．新中医，2000，32(10)：56
183 徐冰．中医药在慢性乙型肝炎治疗中的免疫调节作用．河南中医，2004，24(4)：83-85
184 金介望．中医治疗慢性活动性乙型肝炎的临床观察．中西医结合杂志，1985，(6)：353
185 任豪．四逆散合五苓散加减治疗急性黄疸型肝炎20例，湖北中医，1992，14(5)：55
186 程润泉．四逆散临床应用三则．四川中医，1986，4(8)：131
187 陈继明．慢性肝炎辨治一得．中医杂志，1986，27(3)：13-15
188 蒲青海．黄疸肝炎临证十二法．四川中医，1986，4(8)：201
189 胡晨霞．四逆散的药理与临床研究进展．中国中医药信息杂志，2001，8(增刊)：18
190 Jiang J, Zhou C, Xu Q. Alleviating effects of Si-Ni-San, a traditional Chinese prescription, on experimental liver injury and its mechanisms. Biol Pharm Bull, 2003, 26(8): 1089-1094
191 蒋洁云，徐强．四逆散及其各组成中药对实验性肝损伤的影响．中国天然药物，2004，2(1)：45-49
192 魏伟，刘家骏，刘家琴，等．白芍总苷对乙型肝炎的治疗作用及其前景．中国药理学通 报，2000，16(5)：596-597
193 温树德，吕鲁，范俊珊，等．几种中药的免疫药理及其对乙肝的治疗．医学研究通讯，1997，26(8)：31
194 周金黄．中药药理与临床研究进展．北京：中国科学技术出版社．1992：246
195 常永玲，刘振兰，石秀荣．强力宁治疗慢性活动性肝炎90例临床观察．吉林医学，1993，14(5)：299
196 雨谷．从药理和药化探讨小柴胡汤(三)．国外医学·中医中药分册，1990，12(4)：28
197 陈泽雄，张诗军，罗致强，等．小柴胡汤对慢性乙肝免疫调节及症状的作用．实用中西医结合杂志，1996，9(10)：597
198 刘中景，柳盛，袁有斌．加味小柴胡汤对慢性乙型肝炎患者的免疫调节作用．中国中医药科技，2002，9(4)：234
199 张希东，于清欣，刘中景．拉米夫定联合小柴胡汤抗HBV及调节免疫的临床观察．中西医结合肝病杂志，2004，14(3)：170-171
200 张喜顺．健脾补肾治疗乙肝体会．中国医药论坛，2004，2(10)：84-85
201 王泽荣，吴建成．中药补肾方在体外对乙肝患者外周血淋巴细胞亚群及TNF-α的调节作用．苏州大学学报(医学版)，2003；23(3)：304-306
202 周飞，王灵台，陈建杰，等．拉米夫定和补肾方联合应用治疗慢性乙型肝炎的疗效及对YMDD区域的影响．中国中西医结合杂志，2003，23(6)：417-420
203 Yang PL, Althage A, Chung J, et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. PNAS, 2002, 99(21): 13825
204 徐克成．慢性乙型肝炎的治疗：进展、问题和对策．胃肠病变，2004，9(3)：186-190
205 蒋森，贾静鹏，蒋芳莉．中西医结合治疗慢性乙型肝炎思路与方法探讨．山西中医，2002，18(3)：43-45
206 张宜俊．慢性乙型肝炎抗病毒治疗的浅见．传染病学信息，2002，15(3)：102
207 陈诗慧，郭卫真，刘妮，等．加味四逆散体外抗乙型肝炎病毒的实验研究．中医药学刊，2006，24(3)：478-479
208 陈诗慧，郭卫真，周红燕，等．四逆散体内抗鸭乙型肝炎病毒的实验研究．国际医药卫生导报，2005，11(22)：6-7
209 易学瑞，曾滢，祖萍，等．基因重组(酵母)乙肝疫苗对HBV转基因小鼠细胞免疫调节作用．上海实验动物科学，2003，23(2)：151-153
210 中华医学会传染病与寄生虫病学分会、肝病学分会．病毒性肝炎防治方案．中华肝脏病杂志，2000，8(6)：324-329
211 郑莜萸主编．中药新药临床研究指导原则(试行)．中国医药科技出版社．北京：2002．5．第1版：371-372
212 中华全国中医学会内科肝病专业委员会．病毒性肝炎中医辨证标准(试行)．中医杂 志，1995(5)：39-40
213 程相岭，王兴明．中医辨证调节免疫治疗急慢性乙型肝炎探讨．中西医结合肝病杂志，2002，12(6)：361-361
214 王钦和，李孝保，许成勇．补脾肾、祛湿热、理气血法治疗慢性乙型肝炎．光明中医，2005，20(2)：37-38
215 肖和杰，刘霞，石次国，等．复方淫羊藿治疗慢性乙型肝炎84例．中西医结合肝病杂志，1994，4(增刊)：70-71
216 方曼倩，张友祥，张佳发．中西医结合治疗慢性乙型肝炎的近期疗效观察．中国中医药信息杂志，2001，8(10)：59
217 王严冬．中西医结合治疗慢性乙型肝炎32例疗效观察．河南中医药学刊，2002，17(3)：38-39
218 张建军，王洪京，张红．叶下珠合剂与拉米夫定联合治疗慢性乙型肝炎40例．山东中医药大学学报，2001，25(6)：438
219 陈立华．中医中药治疗病毒性肝炎的疗效．中医杂志，1995，36(10)：621-623
220 C.L. Lai, V. Ratziu, M.F. Yuen,, et al. Viral hepatitis B, Lancet. 2003,362:2089-2094
221 A.K. Raney, R.K. Hamatake, Z. Hong, Agents in clinical development for the treatment of chronic hepatitis B, Expert Opin. Investig. Drugs, 2003, 12:1281-1295
222 刘克洲．中西医结合治疗慢性乙型病毒性肝炎—抗病毒治疗是关键．浙江中西医结合杂志，2005，15(1)：1-3
223 A. M. Rivkin. Adefovir dipivoxil in the treatment of chronic hepatitis B, Ann. Pharmacother. 2004, (38): 625-633
224 D. Sprengers, H. L. Janssen. Immunomodulatory therapy for chronic hepatitis B virus infection, Fundam. Clin. Pharmacol, 2005, 19:17-26
225 王灵台．中西医结合肝病科研的思路与方法．中西医结合肝病杂志，1999，9(3)：1-2
226 姚集鲁．主编．传染病学临床专论．广州：广州高等教育出版社．2002．2
227 陈诗慧，卢焯明．中药治疗乙型病毒性肝炎的进展．中国热带医学，2004，4(1)：137-138
228 赵英杰，范希成．慢性乙型肝炎抗病毒治疗的进展．寄生虫病与感染性疾病，2003，2(1)：34-37
229 张定风．乙型肝炎的发病机理及临床：免疫调节系统的功能．重庆：重庆出版社，1992：151-167
230 张盛杰，陈建杰，奚骏，等．补肾冲剂治疗慢性乙型肝炎32例．中西医结合肝病杂志，2005，15(6)：366
231 高月求，孙学华，章晓鹰，等．补肾方对慢性乙型肝炎T细胞亚群及其功能的影响．中国中西医结合杂志，2005，25(5)：408-411
232 王培兴．疏肝健脾补肾法对乙肝的防治．光明中医，2006，21(1)：61-62
233 李乐，蔡鹏威，伍严安，等．慢性乙肝病毒携带者的细胞免疫功能变化及其与血清HBVDNA的关系．福建医药杂志，2003，25(6)：18-21
234 叶维法，钟振义．肝病免疫学：细胞免疫的病理作用．天津：天津科学技术出版社，1997．109-118
235 吴成．慢性乙型肝炎的中医药实验研究评析．中医药学刊，2002，20(1)：56-58
236 徐春军．乙肝病毒基因变异与中医药治疗策略探讨．中国中医药信息杂志，2002，9(11)：24-25
237 高月求，王灵台，陈建杰．补肾冲剂治疗慢性乙型肝炎的临床研究．上海中医药大学学报，2001，15(1)：34-36
238 李东复，闫峻，周晓琦，等．慢性肝病患者T淋巴细胞亚群、IL-10和IL-12变化的意义．吉林大学学报(医学版)，2004，30(4)：583-585
239 杨宏志，边壮，王拥泽，等．慢性乙型肝炎虚实病机与病毒复制及T细胞关系的研究．中国中西医结合急救杂志，2003，10(3)：158-160
240 B. Rehermann, C. Pasquinelli, S.M. Mosier, F.V. Chisari. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection, J. Clin. Invest. 1995, 96: 1527- 1534
241 L.G. Guidotti, T. Ishikawa, M.V. Hobbs, et al. Intracellular inactivation of the hepatitis B vires by cytotoxic T lymphocytes, Immunity. 1996, 4:25-36
242 L.G. Guidotti, K. Ando, M.V. Hobbs, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice, Proc. Natl. Acad. Sci. U. S. A. 1994, 91: 3764- 3768
243 陈智．慢性乙型肝炎治疗的若干研究进展．浙江大学学报(医学版)，2005，34(2)：95-97
244 Guo JT, Zhou H, Liu C, et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000, 74:1495-1505
245 Mosmann T. Rapid colorimetric assay for cellar growth and survival application to proliferation and cytotoxicity assays. J Immunol Methods, 1983,65:55
246 张跃新，傅希贤，张乃临，等．3种中草药对乙型肝炎病毒复制抑制效果的体外实验研究．新疆医学院学报，1996，19(4)：272-275
247 陈压西，郭树华，齐珍元，等．叶下珠有效部位抗鸭乙型肝炎病毒及体外抗HBV活性的研究．中药药理与临床，1999，15(6)：16-18
248 张振强，王倩嵘．软肝饮对HBV转染细胞表达功能抑制的实验研究．开封医专学报2000，19(1)：42-43
249 Heijtink RA, De Wilde GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res, 1993; 21:141-153
250 张其威，张楚瑜．抗病毒中药研究的最新进展．中成药，2005，27(1)：116-119
251 聂哲云．四逆散加味治疗乙型肝炎99例．恩施医专学报，1994，11(2)：38-40
252 廖云龙，胡志方，徐婉如，等．复方四逆散治疗43例慢性活动性乙型肝炎的临床观察．江西中医学院学报，1996，8(1)：4-5
253 刘星．加味四逆散抗拉米夫定停药后慢性乙型肝炎复发12例．中国中西医结合杂志，2002，22(8)：593
254 任建平，陈蔓芙．茯苓对消化系统疾病影响的研究概述．中国中医药科技，1999，6(1)：63-64
255 蔺学燕，董传海，李伟华．淫羊藿有效成分的药理研究与临床应用．时珍国医国药，2005，16(9)：917-918
256 丁雁，刑善田，周金黄．淫羊藿多糖促进小鼠T和B细胞H-DdR掺入和诱生干扰素作用的研究．中国免疫学杂志，1985，1(6)：42-42
257 丁雁，刑善田，周黄金．淫羊藿多糖致小鼠胸腺缩小的免疫药理研究．中国免疫学杂志，1993，9(3)：185-185
258 丁雁，刑善田，周黄金．淫羊藿多糖和苷的胸腺缩小的免疫药理研究．中国免疫学杂志，1993，9(5)：342-342
259 储岳峰，颜新敏，李祥瑞，等．半定量RT-PCR测定中药成分对小鼠脾T细胞IL-2mRNA水平的影响．中国农业科学，2005，38(9)：1911-1916
260 梅国强．乙型肝炎的中医治疗．北京：科学技术出版社，1995：304-307
261 沈自尹，蔡定芳，张玲娟，等．补肾和健脾对免疫系统不同作用方式的研究．中国中西医结合杂志，1997，17(6)：351
262 白隆华，董青松，蒲瑞翎．中药鸡骨草研究概况．广西农业科学，2005，36(5)：476-478
263 周芳，李爱嫒．鸡骨草与毛鸡骨草抗炎免疫的实验研究．云南中医中药杂志，2005，26(4)：33-34
264 Chon CY, Han KH, Lee KS, et al. Peritoneoscopic liver biopsy findings in asymptomatic chronic HBsAg carriers wit h normal liver function test s and no hepatomegaly. Yonsei Med J, 1996, 37 (5): 295-301.
265 骆抗先，朱幼芙．乙型肝炎：临床与活体组织病理．北京：科学出版社，2001．162-179
266 Chisari FV, Klopchin K. Moriyama T, et al. Molecular pathogenesis of hepatocellular carcionoma in HBV transgenic mice. Cell, 1989, 59:1145
267 Pasquetto V, Wieland S, Chisari FV. Intracellular hepatitis B virus nueleoeapsids survive eytotoxie T-lymphocyte- induced apoptosis. J Virol, 2000, 74:9792-9796
268 Wang KX, Peng JI, Wang XF, et al.Detection of T lymphocyte subsets and mlL-2R on surface of PBMC in patients with hepatitis B. World J Gastroenterol, 2003, 9: 2017-2020
269 Jung MC, Spengler U, Schraut W, et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol. 1991, 13: 310-317
270 Rehermann B, Fowler P, Sidney J, Person J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med. 1995, 181:1047-1058
271 Koziel M J. Cytokines in viral hepatitis. Semin Liver Dis, 1999, 19:157-1699
272 Lau G K. Use of immunomodulatory therapy (other than interfere on) for the treatment of chronic hepatitis B virus infection. J Gastroenterol Hepatol, 2000, 15:46-52
273 黄茵．慢性感染的免疫耐受形成机制．国外医学·流行病学传染病学分册，2001，(2)：57
274 陈亚冈，马亦林，屠中元，等．乙型慢性活动性肝炎患者外周血淋巴细胞亚群及IL-2受体表达．中华传染病杂志，1992，10(1)：48-49
275 万克青，杨旭，郑宣鹤．香茹多糖注射液对慢性活动性肝炎外周血T淋巴细胞亚群和IL-2受体表达作用的研究．中国免疫学杂志，1995，(5)：298
276 毕青，张俊富，温玉焕，等．复方仙灵脾冲剂对慢性乙型肝炎患者slL-2RT淋巴细胞亚群的影响．中西医结合肝病杂志，2000，(1)：14
277 张广业，王育群，张玮．中医药免疫调节治疗慢性乙型病毒性肝炎研究进展．安徽中医临床杂志，2002，14(6)：518-520
278 黄争荣．中药复方对慢性乙型肝炎的免疫调节作用研究进展．福建中医学院学报，2003，13(1)：62-64
279 周春祥，徐强，曹劲松，等．四逆散改善细胞免疫性肝损伤作用机理研究．中国中医基础医学杂志，2002，8(5)：47-49
280 Raney AK, McLachlan A. The biology of hepatitis B virus. Molecular biology of the hepatitis B virus. Boca Raton, FL7 CRC Press; 1991:1-37
281 Babinet C, Farza H, Morello D, et al. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985, 230:1160-1163
282 Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990; 50:3400-3407
283 Lee TH, Finegold MJ, Ring-Fong S, et al. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol 1990, 64:5939-5947
284 Reifenberg K, Lohler J, Pudollek HP, et al. Long-term expression of the hepatitis B virus core-e- and X-protein does not cause pathologic changes in transgenic mice. J Hepatol 1997, 26:119-130
285 Kim CM, Koike K, Salto I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320
286 Chomarat P, Rice JM, Slagle BL, et al. Hepatitis B virusinduced liver injury and altered expression of carcinogen metabolishing enzymes: the role of the HBx protein. Toxicol Lett 1998; 102-103:595-601
287 Yu DY, Moon HB, Son JK, et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999, 31:123-132
288 Penna, A, Del Prete, G., Cavalli, A, et al. Predominant T helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute selflimited hepatitis B. Hepatology. 1997, 25:1022-1027
289 Bertoletti, A, D'Elios, M M, Boni, C, et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology, 1997, 112:193-199
290 Romero, R., and Lavine, J. E. Cytokine inhibition of the hepatitis B virus core promoter. Hepatology, 1996, 23:17-23
291 Guy B, Pascal N, Francon A, et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine, 2001, 19:1794
292 Del Giobbo, Foli A, Balzarini J, et al. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl) adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res. 1991, 16:65-75
293 Cooksley H, Chokshi S, Wedemeyer H, et al. Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: a multicentre, controlled study. J Hepatol. 2002, 36:7
294 周娟，李连闯，毕明刚，等．慢性乙肝的细胞免疫病毒和中药与植物药治疗．国外医药·植物药分册，2006，21(5)：202-206
295 顾缨．中药免疫调节剂治疗乙型病毒性肝炎的研究近况．中医药临床杂志，2005，17(3)：311-312
296 Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol, 2000, 12:403-408
297 Boni C, Penna A, Ogg GS, Bertoletti A, et al. Lamivudine treatment can overcome cytotoxic Tcell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology, 2001, 33:963-971
298 Alexander GJW, Mondelli M, Naumov NN, et al. Functional characterization of peripheral blood lymphocytes inchronic HBsAg carders. Clin Exp Immunl, 1986, 63:498